

This item is the archived peer-reviewed author-version of:

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Reference:

Song Lijun, Merceron Romain, Hulpia Fabian, Lucía Ainhoa, Gracia Begoña, Jian Yanlin, Risseeuw Martijn D.P., Verstraelen Toon, Cos Paul, Aínsa José A., ...- Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors
European journal of medicinal chemistry - ISSN 1768-3254 - 225(2021), 113784
Full text (Publisher's DOI): <https://doi.org/10.1016/J.EJMECH.2021.113784>
To cite this reference: <https://hdl.handle.net/10067/1811910151162165141>

[Title page – *European Journal of Medicinal Chemistry*]

Structure-aided optimization of non-nucleoside *M. tuberculosis* thymidylate kinase inhibitors

Lijun Song,^{1,x} Romain Merceron,^{2,3,y} Fabian Hulpia,^{1,z} Ainhoa Lucía,^{4,5} Begoña Gracia,^{4,5} Yanlin Jian,¹ Martijn D.P. Risseeuw,¹ Toon Verstraelen,⁶ Paul Cos,⁷ José A. Aínsa,^{4,5} Helena I. Boshoff,⁸ Hélène Munier-Lehmann,^{9,10} Savvas N. Savvides,^{2,3} Serge Van Calenbergh^{1,*}

1. Laboratory for Medicinal Chemistry (FFW), Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium
2. VIB Center for Inflammation Research, Zwijnaarde (Ghent) 9052, Belgium
3. Department of Biochemistry and Microbiology, Ghent University, Technologiepark 927, 9052 Zwijnaarde (Ghent), Belgium
4. Grupo de Genética de Micobacterias, Departamento de Microbiología, Facultad de Medicina, and BIFI, Universidad de Zaragoza, Zaragoza, Spain
5. CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain.
6. Center for Molecular Modeling, Ghent University, Zwijnaarde, Ghent 9052, Belgium

7. Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Department of Pharmaceutical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, B-2610 Antwerpen, Belgium
8. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
9. Unit of Chemistry and Biocatalysis, Department of Structural Biology and Chemistry, Institut Pasteur, 75724 Paris Cedex 15, France
10. CNRS UMR3523, Paris, France

Current affiliation:

^x 3M, Zwijndrecht, Belgium

^y Eurofins group, Poitiers, France

^z Janssen Pharmaceutica, Beerse, Belgium


ABSTRACT

Mycobacterium tuberculosis thymidylate kinase (*Mt*TMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside *Mt*TMPK inhibitors in an effort to diversify *Mt*TMPK inhibitor chemical space. We here report a new series of *Mt*TMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by co-crystal structures of *Mt*TMPK in complex with developed inhibitors. These efforts furnished the most potent *Mt*TMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the *Mt*TMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.

Keywords

Mycobacterium tuberculosis, thymidylate kinase, structure-based inhibitor design

Table of contents graphic (also on last page)



1. INTRODUCTION

Tuberculosis (TB) in humans is caused by the bacterium *Mycobacterium tuberculosis* (Mtb) and has become the most lethal infectious disease ranking among the top ten causes of death worldwide.¹ In 2016, 10.4 million cases of active TB were reported while 1.3 million people were estimated to have died from Mtb infection.¹ Tuberculosis is generally manifested as a respiratory disease affecting the lungs, although other sites on the human body can also be affected. After exposure to Mtb, the host immune system may eliminate the infection; latent asymptomatic TB infection can also be established, which may develop into active TB in case of immunosuppression. Pulmonary TB is a chronic disease with typical symptoms such as fever, weight loss and cough, leading to death over the years. However, if the patient is co-infected with human immunodeficiency virus (HIV), death could occur within 4 weeks, including the diagnosis time.² TB contributes heavily to the mortality of HIV-infected patients. Moreover, drug-resistant TB has become a global issue with the alarming emergence of resistant strains.¹ Therefore, drugs with a novel mode of action and scaffolds are urgently needed to combat TB.

M. tuberculosis thymidine monophosphate kinase (*Mt*TMPK) is a phosphotransferase that phosphorylates thymidine monophosphate (TMP) to thymidine diphosphate (TDP), which is then further transformed into thymidine triphosphate (TTP).³⁻⁵ Its essentiality for the survival of Mtb and the druggability of the TMP-binding site have been proven via high-resolution phenotypic profiling⁶ and sitemap analysis,⁷⁻⁸ respectively. Additionally, the availability of X-ray co-crystal structures of *Mt*TMPK⁸⁻¹¹ allow rational drug design.

In previous work from our group, hit compound **1** (Figure 1) was discovered as a promising scaffold for the elaboration of *Mt*TMPK inhibitors.¹¹ While retaining the thymine moiety (ring A), which mediates key interactions with the active site of the enzyme, modifications of ring B or the spacer between ring A and B were found to negatively influence the inhibitory activity. Attempts to truncate the structure by removal of ring D increased ligand efficiency,¹² but failed to afford compounds with antimycobacterial activity (Figure

1). Further modification led to phenoxy-quinoline-type analogues (compound **2**), some of which exhibited potent enzymatic activity and moderate whole-cell activities. The aim of this study was to design *Mt*TMPK inhibitors with different physicochemical properties (i.e. increase polarity) in an effort to increase the solubility and potentially identify analogues with improved whole-cell activity.¹³⁻¹⁴





Figure 1. Overview of previous (upper line) and current (lower line) modifications of hit compound **1**¹¹.

Optimization of the tetracyclic structure (rings A-B-C-D), spanned three stages (Figure 1). First, the phenyl ring (ring C) was replaced by a pyridyl unit, of which all possible positions of the nitrogen were investigated (series 1), while retaining the *meta*-relationship^{11, 15} of the piperidinyll and phenoxy substituent (Figure 2, upper part). Alternatively, the terminal D-ring was replaced by a range of different rings (series 2) with diverging lipophilic and electronic properties (Figure 2, lower part). Finally, the most promising modifications that arose from stage 1 as well as stage 2 were combined to yield a third series (Figure 3).




3: W = N; X = Y = Z = CH

4: X = N; W = Y = Z = CH

5: Y = N; W = X = Z = CH

6: Z = N; W = X = Y = CH



R =



7



8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24



25



26



27

Figure 2. Structures of prepared analogues in this study. Structures of analogues with a pyridine C-ring (upper part), and structures of analogues with a modified D-ring (lower part).




Figure 3. Hybrid analogues (Series 3) comprised of elements investigated from Series 1 and 2.

2. RESULTS AND DISCUSSION

2.1. Synthesis

In general, all target analogues were synthesized by means of a sequence of reductive amination between an appropriate aromatic aldehyde and BOM-protected 4-piperidinylthymine,¹⁵ followed by acid-mediated BOM deprotection,¹¹ to reveal the desired final compounds.


The synthetic routes to obtain the required aromatic aldehydes to prepare series 1 and 3 are depicted in Scheme 1. The successful synthetic route of the aldehyde precursor depended on the desired substitution pattern of the pyridine ring. For C-2/6 and C-2/4 substituted pyridines, the appropriate 2-bromopyridine-aldehydes (**37** or **41**, respectively) were first protected as cyclic acetals. Ullmann coupling with either phenol or 3-chlorophenol, followed by deprotection gave the desired aldehydes **39**, **40**, **43** and **44** (Scheme 1).¹⁶ Generally, the Ullmann coupling with 3-chlorophenol gave substantially higher yields than with phenol.

This sequence (protection-Ullmann coupling-deprotection) was found unsuitable for the synthesis of the remaining pyridine isomers (**46-48**, **51**, **53**, **55** and **59**), possibly due to altered electronic in the pyridine ring (data not shown). For C-4 substituted 2-pyridinecarbaldehydes, the synthesis started from 4-bromo-2-methylpyridine **45**, which was reacted with the appropriate phenol under Ullmann coupling conditions.^{11, 16} Notably, the Ullmann reaction with 3,5-dichlorophenol required harsher reaction conditions to force coupling.¹⁷ Next, oxidation of the methyl group with selenium dioxide yielded aldehydes **46-48**.

The synthesis of 5-substituted 3-pyridinecarbaldehydes started from methyl-5-hydroxynicotinate **49**, which was reacted with the appropriate phenylboronic acid under Chan-Lam coupling conditions to afford compounds **50**, **52** and **54**. Finally, a reduction/re-oxidation sequence, employing LiAlH₄ and MnO₂, furnished the desired aldehydes **51**, **53** and **55**. Chan-Lam coupling between 3,5-dichlorophenylboronic acid and **49**, however, failed to yield the desired product, as did an Ullmann coupling between 3,5-dichloro-

iodobenzene and **49** using picolinic acid as the ligand.¹⁸ Finally, reversal of the coupling partner polarity (bromopyridine **56** and 3,5-dichlorophenol) yielded intermediate **57**, under the same conditions as those used for the preparation of **48**. Direct oxidation of the aromatic methyl group to the corresponding aldehyde with selenium dioxide at 120 °C failed to give the desired aldehyde.¹⁹ However, oxidation of **57** to the corresponding carboxylic acid (**58**) with aq. KMnO₄ was successful. Transformation of **58** to its methyl ester, followed by LiAlH₄ reduction and re-oxidation with Dess-Martin periodinane furnished the desired aldehyde **59**.


Scheme 1. Synthesis of required aldehydes for pyridine and hybrid analogues (Series 1 and 3).



Reagents and conditions: (a) 1,3-dihydroxypropane (1.2 eq), p-toluenesulfonic acid (cat.), toluene, reflux (Dean-Stark), 3 h; (b) (i) appropriate phenol, Cs₂CO₃ (3 eq), *N,N*-dimethylglycine.HCl (0.3 eq), CuI (0.1 eq), 1,4-dioxane, dry air, 90 °C, 24 h; (ii) THF/2M aq. HCl (V/V, 1/1), 60 °C, 2-7 h; (c) (i) 3,5-dichlorophenol, K₃PO₄, picolinic acid, CuI, dry DMF, argon, 140 °C, 24 h; (ii) SeO₂, 1,4-dioxane, 80 °C, overnight (compound **46** and **47**) or 100 °C, 24 h (compound **48**); (d) appropriate phenylboronic acid (3 - 3.5 eq), Cu(OAc)₂ (2 eq), Et₃N (7 eq), 4Å molecular sieves, DCM, air, rt; (e) (i) LiAlH₄, dry THF, rt; (ii) MnO₂, DCM, rt; (f) KMnO₄, pyridine/H₂O, reflux, 7 h; (g) (i) SOCl₂, MeOH, rt to reflux, overnight; (ii) LiAlH₄, dry THF, rt; (iii) Dess-Martin reagent, DCM, rt.

Analogues with a modified D-ring (**7-27**) were synthesized as depicted in Scheme 2. For selected analogues with N-containing D-rings (**7-9**), 3-the appropriate pyridinyl halides and protected hydroxybenzaldehyde (**61**) were employed for the Ullmann coupling. The cyclo-alkyl substituted aldehydes **66** and **68** were synthesized via Mitsunobu reaction.²⁰ In other cases substituted phenols and protected halo aldehydes (**69** and **71**) were preferred. The synthesis of compound **19** involved reductive amination of 3-bromobenzaldehyde **80** with BOM-protected 1-(piperidin-4yl)thymine, followed by Ullmann coupling with mono-TBDMS-protected resorcinol **83**. Conveniently, the silyl group was removed under Ullmann coupling condition, but in view of the low yield of this approach, we decided to prepare the other required aromatic aldehydes as described earlier: acetal protection, Ullmann coupling and acetal deprotection.

Scheme 2. Synthesis of D-ring modified derivatives (Series 2).




Reagents and conditions: (a) (i) Ac₂O, pyridine, 0 - 25 °C, 1 h; (ii) 1,3-dihydroxypropane, *p*-toluenesulfonic acid, toluene, reflux (Dean-Stark), 3 h; (iii) 10% aq. NaOH, 2 h; (b) (i) Cs₂CO₃ (3 eq), *N,N*-dimethylglycine.HCl (0.3 eq), CuI (0.1), 1,4-dioxane, argon, 90 °C, 24 h; (ii) THF/2M aq. HCl (V/V, 1/1), rt, 2-7 h; (c) (i) V1-H, NaBH(OAc)₃, dry DCE, r.t. overnight; (ii) 80% TFA/H₂O, 0.25–0.27 M L-cysteine,

72 °C, 3-12 h; (d) Ph₃P, diisopropyl azodicarboxylate, dry THF, reflux, 24 h. (e) 1,3-dihydroxypropane (1.2 eq), p-toluenesulfonic acid (cat.), toluene, reflux (Dean-Stark), 3 h; (f) V1-H, NaBH(OAc)₃, dry DCE, rt, overnight; (g) TBDMSCl, imidazole, DMF, rt, overnight; (h) (i) K₃PO₄, picolinic acid, CuI, dry DMSO, 140 °C, argon, 24 h; (ii) 80% TFA/H₂O, 0.27 M L-cysteine, 72 °C, 5 h.

The methods to access derivatives of analogue **3** (**28** and **29**) are described in Scheme 3. Synthesis of aldehyde **94** started from hydroquinone. First, mono-OH silyl-protection gave **93**, which was used for the Ullmann coupling with **38**. Sequential silyl and acetal deprotection afforded the required aldehyde **94**. For the synthesis of carboxylic acid **29**, we first attempted an Ullmann coupling of **38** with 2-hydroxybenzotrile. However, final hydrolysis (after acetal deprotection) of the cyano group only gave rise to the amide intermediate, even upon heating at reflux for an extended period of time in aqueous potassium hydroxide solution (data not shown). Alternatively, Ullmann coupling with methyl 2-hydroxybenzoate, followed by ester hydrolysis furnished the desired product after reductive amination and final BOM deprotection.

Scheme 3. Synthesis of derivatives of analogue **3** (analogue **28** and **29**).









Reagents and conditions: (a) TBDMSCl, imidazole, DMF, rt, overnight; (b) (i) **38**, Cs₂CO₃ (3 eq), *N,N*-dimethylglycine.HCl (0.3 eq), CuI (0.1 eq), 1,4-dioxane, argon, 90 °C, 24 h; (ii) 1M TBAF in THF, THF, rt, 3 h; (iii) THF/2M aq. HCl (V/V, 1/1), 55 °C, 3 h; (c) (i) V1-H, NaBH(OAc)₃, dry DCE, rt, overnight; (ii) 80% TFA/H₂O, 0.25–0.27 M L-cysteine, 72 °C, 3–12 h; (d) (i) methyl 2-hydroxybenzoate, K₃PO₄, picolinic acid, CuI, dry DMSO, 90 °C, argon, 24 h; (ii) THF/2M aq. HCl (V/V, 1/1), rt; (e) (i) V1-H, NaBH(OAc)₃, dry DCE, rt, overnight; (ii) NaOH, H₂O/THF, rt, 2 days; (iii) 80% TFA/H₂O, 0.25 M L-cysteine, 72 °C, 3–12 h.

2.2. Biological evaluation

In our previous work, structure-guided modification of compound **1** led to phenoxyquinoline analogue **2**, which exhibited improved enzymatic and cellular activity.¹¹ This investigation also indicated that efflux pumps are, at least, partially responsible for the discrepancy between the moderate (or lack of) whole-cell activity on the one hand, and the high *Mt*TMPK inhibitory activity of phenoxyquinoline derivatives on the other hand. Nevertheless, we also hypothesized that the main reason for this disparity could also be ascribed to low permeability of the reported *Mt*TMPK inhibitors through the thick mycobacterial cell wall and its crystalline-like mycolate layer.²¹⁻²² Additionally, for selected analogues *in vitro* assessment of the antimycobacterial activity was also hampered by poor aqueous solubility, which was particularly relevant for phenoxyquinoline analogues. To potentially address this solubility issue and to identify compounds that might accumulate better in the bacteria, we thus introduced a nitrogen atom in ring C of lead compound **1** (Figure 2 and Table 1), to increase overall polarity. The resulting pyridine analogues **3-6** had comparable *Mt*TMPK inhibitory activity as **1**, but failed to show *in vitro* antitubercular activity, except for the 3,5-substituted analogue **5**, which displayed weak antitubercular activity. The co-crystal structure of compound **3**, the most potent enzyme inhibitor pyridine isomer of this series, with *Mt*TMPK was successfully solved (*vide infra*).












Table 1. *Mt*TMPK inhibitory activity and antimycobacterial activity (MIC) against *M. tuberculosis* H37Rv of analogues in Series 1. Cytotoxicity was assayed in human fibroblast cells (MRC-5). The *Mt*TMPK inhibitory activity value for analogue **1** was taken from reference ¹⁵.

|  | | | | | |
|--|---|-------|---------------------------------------|--------------------------|-----------------------------|
| No | X | ClogP | IC ₅₀ (μM, <i>Mt</i> TMPK) | MIC (μM, H37Rv, Glucose) | MRC-5 EC ₅₀ (μM) |
| 1 |  | 2.86 | 6.1 ± 0.5 ¹⁵ | N.D. | N.D. |
| 3 |  | 2.66 | 2.5 ± 0.3 | >50 | >64.0 |
| 4 |  | 1.94 | 8.7 ± 0.4 | >50 | >64.0 |
| 5 |  | 1.52 | 6.4 ± 0.4 | 37 | >64.0 |
| 6 |  | 2.23 | 10.2 ± 1.0 | >50 | >64.0 |

To further expand the SAR information, we introduced different substituents on phenyl D-ring of **1** or replaced it by pyridyl and cycloalkyl rings (Table 2). The *Mt*TMPK inhibitory activity of the pyridyl substituted analogues (**7-9**) was inferior to that of **1** and the C-ring pyridine analogues of series 1. The inferior inhibitory potency of cycloalkyl substituted compounds (**10** and **11**) suggests that a planar D-ring is preferred. The substituents introduced on the D-ring of **1** were selected via Topliss scheme, a decision tree that relies on lipophilicity (π), electronic effect (σ) and steric effect (E_s) of the aromatic substituents.²³ While the effect on the enzyme inhibitory potency of a 4-Cl-substituent (**12**, + π , + σ) is comparable to that

of lead **1** (4-H, $\pi = 0$, $\sigma = 0$), introduction of a 4-MeO (**13**, - π , - σ) and 4-Me (**14**, + π , - σ) yielded inferior activities, indicating that substituents at the *para*-position are sterically not well tolerated. A 3-Cl substitution (**16**, + π , + σ), on the other hand, showed a significant improvement in *Mt*TMPK inhibitory activity. Consistently, analogue pairs **15/16** (3,4-Cl₂/3-Cl), **21/23** (3-CF₃-4-Cl/3-CF₃) and **22/18** (3,4-F₂/3-F) demonstrate that *Mt*TMPK better accommodates 3-substituted over 3,4-substituted analogues. Following application of Topliss tree for 3-substituted analogues, analogues **23** (3-CF₃) and **24** (3-CF₃O) further improved the enzyme inhibitory activity, while analogues **17** (3-Me), **19** (3-OH) and **20** (3-MeO) with electron-donating groups gave weaker inhibitory activities. Most interestingly, the 3,5-disubstituted analogues **25** (3,5-Cl₂) and **27** (3,5-(CF₃)₂) resulted in highly potent *Mt*TMPK inhibitors. Thus we conclude that ring D prefers lipophilic, electron-withdrawing groups, preferably not in the *para* position. With regard to whole-cell activity against *M. tuberculosis*, analogues **15**, **16** and **25** displayed encouraging *in vitro* activity. Although more potent enzyme inhibitors are clearly also more potent antitubercular compounds, the correlation is rather poor (compare analogues **25** and **27**). Unfortunately, **15**, **26** and **25** were poorly selective with respect to mammalian cells, limiting their development potential. Next, we verified that cytotoxicity is not due to inhibition of human TMPK (hTMPK) by assaying selected analogues (**15**, **21**, **24** and **25**), which revealed no inhibition of hTMPK up to a concentration of 40 μ M.

Table 2. *Mt*TMPK inhibitory activity and antimycobacterial activity (MIC) against *M. tuberculosis* H37Rv of analogues in Series 2. Cytotoxicity was assayed in human fibroblast cells (MRC-5). *see Table 4 for activity of the compound against H37Rv.

|  | | | | | |
|--|---|-------|---------------------------------------|--|--------------------------------|
| No | R | ClogP | IC ₅₀ (μM, <i>Mt</i> TMPK) | <i>Mtb</i> H37Rv MIC (μM, glucose) | MRC-5 EC ₅₀ (μM) |
| 7 |  | 2.23 | 41 ± 7 | >50 | >64.0 |
| 8 |  | 1.52 | 27 ± 8 | >50 | >64.0 |
| 9 |  | 1.52 | 20 ± 2 | N.D. | N.D. |
| 10 |  | 2.32 | 32 ± 2 | >50 | 30.3 ± 3.1 |
| 11 |  | 2.74 | 42 ± 3 | 37 | 23.6 ± 3.0 |
| 12 |  | 3.41 | 6.9 ± 0.7 | 12.5 | 25.1 ± 2.6 |
| 13 |  | 2.73 | 10.5 ± 0.5 | * | 28.0 ± 1.9 |
| 14 |  | 3.34 | 12 ± 1 | * | [>64.0; 24.0] |
| 15 |  | 3.97 | 1.1 ± 0.3 | 12.5 | 6.10 ± 0.10 |
| 16 |  | 3.41 | 0.89 ± 0.12 | 12.5 | 21.0 ± 3.7 |

| | | | | | |
|----|---|------|-----------------|------|-----------------|
| 17 |  | 3.34 | 26 ± 1 | 37 | >64.0 |
| 18 |  | 3.01 | 2.9 ± 0.5 | 25 | >64.0 |
| 19 |  | 2.47 | 3.3 ± 0.3 | N.D. | >64.0 |
| 20 |  | 2.73 | 1.2 ± 0.1 | 25 | 25.3 ± 5.7 |
| 21 |  | 4.34 | 1.1 ± 0.1 | 25 | 5.28 ± 0.22 |
| 22 |  | 3.17 | 2.6 ± 0.6 | 19 | >64.0 |
| 23 |  | 3.78 | 0.60 ± 0.19 | 19 | 12.4 ± 6.6 |
| 24 |  | 4.38 | 0.65 ± 0.06 | 25 | 5.26 ± 0.40 |
| 25 |  | 3.97 | 0.12 ± 0.01 | 12.5 | 6.73 ± 0.50 |
| 26 |  | 3.17 | 2.8 ± 0.8 | >50 | >64.0 |
| 27 |  | 4.7 | 0.14 ± 0.01 | >50 | N.D. |

To gain insights into the binding mode of inhibitor **3** we determined the crystal structure of *Mt*TMPK in complex with **3** (PDB code 5NRN) to 2.2 Å resolution. Inhibitor **3** which behaves as a competitive inhibitor, binds with full occupancy in the active site of the enzyme where it adopts a U-turn shaped conformation (Figure 4). The thymine ring (ring A) interacts with residues lining the catalytic pocket in a configuration reminiscent to the one previously described for *Mt*TMPK structures in complex with dTMP and thymine-

like inhibitors. Ring A is stabilized via hydrophobic interactions between its C⁵ methyl group and Arg95, Pro37 and Phe36 side chains. In addition to a π - π stacking interaction between ring A and Phe70, the inhibitor is further stabilized via hydrogen bonds linking the O⁴ and N³ groups of the thymine ring with Arg74 and Asn100 respectively. The *para*-piperidine ring (ring B), modelled in a chair conformation, protrudes out of the active site and is located in a similar position to the 2'-deoxyribose ring of dTMP establishing a π -alkyl interaction with the aromatic side chain of Tyr103. In chain A, the pyridyl ring (ring C) protrudes out of the active site where it does not establish any specific interaction with the enzyme. Conversely, ring C establishes a CH-alkyl interaction with residue Arg153 which belongs to the LID loop, and which is in a closed conformation in chain B (the same loop is disordered in chain A). The LID loop in chain B establishes contacts with neighboring symmetry related molecules and its conformation might be the result of crystal packing leading to some questioning about the validity of this later interaction. The benzene ring (ring D) is accommodated in a pocket formed by residues Leu52 and Arg107 and ring C provides the compound with the necessary spacer to adopt this U-turn shaped conformation.




Figure 4. Structural characterization of the binding pose of compound **3** in *Mt*TMPK active site (deposited as PDB code 5NRN). (A) Co-crystal structure of compound **3** bound to *Mt*TMPK at 2.2 Å resolution. The protein is depicted in pale yellow cartoon representation. Compound **3** (stick representation, carbon atoms in white) and the side chains of *Mt*TMPK interacting residues (stick representation, carbon atoms in orange) are highlighted. The corresponding σ -weighted $F_o - F_c$ difference electron density map (contoured to +4 σ r.m.s.d.) and calculated before adding the ligand in the refinement process is shown as a green mesh. (B) Schematic drawing of compound **3** binding site displaying key *Mt*TMPK interacting residues (hydrogen bonds are represented with a red dashed line). Compound **3** comprises four rings named A to D.

For compound **3**, the electron-pair repulsion between oxygen and nitrogen tends to stabilize a U-shaped conformer, which is preferred by the binding pocket of the enzyme (Figure 6).²⁴ For analogues **4** and **5**, the influence of the electron-pair repulsion is less pronounced, while compound **6** is unlikely to adopt the U-shaped conformation. This is in agreement with the observed trend in IC_{50} -values for these isomers.




Figure 5. Conformational preferences of analogues **3** and **6** due to electron-pair repulsion. The favoured conformation of each compound is shown in blue.

According to the overlay of **3** and TMP crystallographic poses in the active site of *Mt*TMPK, the interaction of the thymine moiety of **3** with the enzyme is quasi-identical as that found in the crystal structure of the dTMP substrate with the enzyme (Figure 6). Interestingly, the D-ring of **3** bends to occupy the position of Tyr165 in the co-crystal of dTMP. In the latter structure, the phenol ring of residue Tyr165 establishes specific interactions via its hydroxyl group with residues Arg107 and with the O⁴ group of the thymine ring via a water molecule. This particular observation inspired us to synthesize analogue **28**, featuring a *para*-hydroxyphenyl D-ring as to mimic this tyrosine. This operation resulted in a two-fold affinity gain compared to analogue **3** (Table 3).




Figure 6. Crystal structure of *Mt*TMPK in complex with dTMP (PDB code 1G3U) showing the binding of the substrate (stick representation, carbon atoms in cyan) in the *Mt*TMPK active site. The protein is depicted in pale-yellow as a ribbon representation. Residue Tyr165 in the LID loop and in close interaction with the substrate is depicted in stick representation with carbon atoms in cyan. The pose of **3** (stick representation, carbon atoms in white) in *Mt*TMPK/**3** co-crystal structure has been overlaid with dTMP. The superimposition shows a strict conservation of the thymine core position and a similar position for the phenol ring of Tyr165 and ring D in **3**. Tyr165 establishes a hydrogen bond with Arg107 and with dTMP via a water molecule. Hydrogen bonds are represented with red dashed lines.

The co-crystal structure of **3** further suggested the possibility to establish an interaction with Arg153 via introducing an *o*-carboxylic group in its D-ring as shown in the docking model (Figure 7). However, **29** failed to show enhanced *Mt*TMPK inhibitory activity (Table 3).















Figure 7. Docking model of compound **29** (carbon atoms in cyan) in *MtTMPK*'s active site, highlighting the envisaged electrostatic interaction (red dashed line) between the carboxyl moiety and Arg107 and Arg153 of the LID loop (depicted in pink) in close proximity to ring D. The co-crystal structure of *MtTMPK* (pale yellow ribbon representation) with compound **3** (stick representation, carbon atoms in white) was used as a template. Key *MtTMPK* interacting residues with **3** are shown in orange for carbon atoms.

Based on the SAR within series 2, we decided to synthesize analogues **30-36**, which combine a pyridine ring C with the most promising D-ring substitution pattern, e.g. 3-CF₃O or 3,5-Cl₂ (Table 3). Introduction of these modifications furnished the most potent enzyme inhibitors of series 3. Specifically, the 3-Cl/CF₃O substituents lower the enzymatic activity by 3-8 fold compared to analogues of series 1 (**3/30**, **4/31**, **5/33**, **5/34**, **6/36**). Following the same SAR discovered from derivatives of series 2, 3,5-Cl₂ even resulted in further improvement in enzyme inhibitory potency (**31/32**, **33/35**), indicating that a hydrophobic and electron-poor D-ring is favorable for inhibitory activity, and thus confirming our earlier observation. A co-

crystal structure of one of the potent *Mt*TMPK inhibitors resulting from this endeavor, i.e. **33**, was solved at 2.1 Å resolution (PDB code: 5NRQ) and is shown in Figure 8.

Table 3. *Mt*TMPK inhibitory activity and antimycobacterial activity (MIC) against *M. tuberculosis* H37Rv of analogues in Series 3. Cytotoxicity was assayed in human fibroblast cells (MRC-5).

|  | | | | | | |
|---|---|---------------------|-------|--|--------------------------------|---------------------------------|
| No | X | R | ClogP | IC ₅₀ (μM, <i>Mt</i> TMPK) | MIC (μM, H37Rv, glucose) | IC ₅₀ (μM, MRC-5) |
| 3 |  | - | 2.66 | 2.5 ± 0.3 | >50 | >64.0 |
| 28 |  | 4-OH | 2.27 | 1.1 ± 0.1 | >50 | N.D. |
| 29 |  | 2-CO ₂ H | 2.22 | 25 ± 2 | >50 | N.D. |
| 30 |  | 3-Cl | 3.22 | 0.45 ± 0.07 | 31 | >64.0 |
| 31 |  | 3-Cl | 2.50 | 2.8 ± 0.7 | >50 | >64.0 |
| 32 |  | 3,5-Cl ₂ | 3.06 | 0.60 ± 0.09 | 34 | N.D. |
| 33 |  | 3-Cl | 2.08 | 0.77 ± 0.09 | 31 | [>64.0; 39.9] |
| 34 |  | 3-CF ₃ O | 3.05 | 0.81 ± 0.01 | 37 | >64.0 |
| 35 |  | 3,5-Cl ₂ | 2.64 | 0.22 ± 0.01 | 43 | >64.0 |

| | | | | | | |
|----|---|------|------|---------------|----|---------------|
| 36 |  | 3-Cl | 2.79 | 3.1 ± 0.2 | 37 | [>64.0; 58.9] |
|----|---|------|------|---------------|----|---------------|




Figure 8. Crystal structure of *Mt*TMPK in complex with compound **33** at 2.1 Å resolution and key interactions with the enzyme (deposited as PDB code 5NRQ). (A). *Mt*TMPK is shown in pale yellow cartoon representation. Compound **33** and the side chains of interacting residues of *Mt*TMPK are represented as grey and orange sticks for carbon atoms, respectively. The corresponding σ -weighted $F_o - F_c$ difference electron density map (contoured to +3 σ r.s.m.d.) and calculated before adding the ligand in the refinement process is shown as a green mesh. (B) Schematic drawing of compound **33** binding site displaying key *Mt*TMPK residues in direct contact with **33** (hydrogen bonds are represented with a red dashed line).

Inhibitor **33**, which is bound in the active site of the enzyme, was positioned in the residual $F_{\text{obs}}-F_{\text{calc}}$ electron density and adopts a similar U-turn shaped conformation with the one observed in **3** complexed structure (Figure 5 and 8). The *Mt*TMPK/**33** co-crystal structure shows identical binding modes for rings A and B relative to the structure of *Mt*TMPK in complex with **3** with all major interactions conserved. The main difference between the two bound inhibitors arises from the relative orientation of ring C and D compared to ring A and B. Indeed, there is a notable conformational difference between **3** and **33** in the corresponding co-crystal structures (Figure 5 and 8), which is well captured by changes of 30° to 40° in torsions angles around bonds between ring B and C and between ring C and D. We assume that the conformational state of **33** compared to **3** is necessary to prevent a potential intramolecular steric clash between the chloro-substituent in ring D and the O⁴ group in ring A. An other difference between **3** and **33** concerns the position of the nitrogen atom in ring C, for which no specific direct interactions with the binding pocket has been detected. Of note, the conformational change observed in **33** complexed structure leads to a different positioning of the pyridyl ring (ring C) which now establishes an edge-to-face π -stacking interaction with residue Tyr103 side chain. Despite this conformational change, ring D conserved its specific CH- π stacking interaction with residue Leu52 side chain in the pocket formed by residues Leu52 and Arg107.

Although analogues in series 3 exhibit potent enzymatic activity, only moderate to weak activity against *M. tuberculosis* H37Rv strain was observed (Table 4). No cytotoxicity was noted among the analogues having a pyridine ring C. Additionally, analogue **30** nor **35** inhibited hTMPK at a concentration of 40 μM and 31 μM , respectively.

In an effort to explain the gap between enzymatic and cellular potency, the MIC-value of some representative compounds was determined in the presence of efflux pump inhibitors or by using mutant

strains. As shown in Table 4, the antimycobacterial activities of most of the investigated compounds are not affected by efflux inhibitors verapamil or PA β N, except for compound **3**, whose activity was moderately improved by the efflux inhibitor verapamil.²⁵ Similarly, deletion of the efflux pumps Tap (Rv1258c)²⁶ or Mmr (Rv3065)²⁷ in Mtb H37Rv strain did not significantly alter susceptibility to the assayed compounds (Table 4).

| Compound | MIC (μ g/mL) | | | | |
|-----------|-------------------|----------------------|-------------------------|------------|------------|
| | H37Rv | H37Rv + verapamil | H37Rv + PA β N | KO Tap | KO Mmr |
| 3 | >250 | 125-62.5 | 125 | >250 | >250 |
| 13 | 31.25 | 31.25-15.6 | 15.6 | 31.25 | 31.25-15.6 |
| 14 | 31.25-15.6 | 15.6 | 15.6 | 31.25-15.6 | 31.25-15.6 |
| 25 | 31.25-15.6 | 15.6-7.8 | 15.6-7.8 | 15.6 | 31.25-15.6 |
| 36 | 31.25-15.6 | 31.25-15.6 | 31.25 | 31.25 | 31.25 |

Table 4. Minimal inhibitory concentrations (MICs) of compounds against *M. tuberculosis* H37Rv with or without efflux pump inhibitors (verapamil, PA β N) and mutant strains (KO Tap, KO Mmr).

The data presented in Table 4 show that efflux is probably not able to account for the activity gap between target and Mtb bacilli of the newly prepared inhibitors in this manuscript. Additionally, we initially hypothesized that perhaps more polar compounds would be able to overcome this, we evaluated whether a

correlation between calculated LogP and MIC values could be identified, as has been proposed in literature,^{13, 28-30} however, we were unable to identify any meaningful correlation.

Interestingly, recent work from GSK³¹ on structurally similar benzylpiperidines, disclosed potent mycobacterial activity, which prompted us to further investigate whether permeability is an issue of our inhibitors. The first-line antibiotic, ethambutol (EMB)³²⁻³³ and thioridazine (TZ)³⁴ are known to alter membrane permeability of Mtb, and can therefore be used in co-incubation experiments to check for potential synergy, which, if identified, is indicative for issues with permeability. Thus, we co-incubated three inhibitors (**3**, **15** and **36**) with EMB and TZ at one fourth of the MIC values (MIC EMB = 2 µg/mL and MIC TZ = 7.8 µg/mL) of the antibiotics. Unfortunately, no significant differences could be observed in the presence or absence of EMB or TZ (data not shown).

3. CONCLUSION

To further exploit the potential of the earlier discovered *Mt*TMPK inhibitor **1**, this study investigates the structure-activity relationship of this identified lead compound. Structure-guided and Topliss-scheme-directed modifications led to the identification of potent *Mt*TMPK inhibitors, which are among the most potent ever identified in our assay. Two enzyme-inhibitor co-crystal structures were obtained, providing insights into a new binding mode of the biphenylether tail region in the enzyme. Unfortunately, all chemistry-related efforts to overcome the difficulties to translate active enzyme inhibitors to potent antibiotics were met with failure. Nevertheless, selected compounds such as **15** and **25** displayed interesting activity (MIC ~ 12.5 µM), they lack sufficient selectivity with respect to human fibroblasts to render them suitable candidates for further development. Additionally, we verified that the observed cytotoxicity was not due to off-target inhibition of hTMPK. Studying selected compounds in efflux pump mutant strains or by co-incubation with efflux inhibitors indicated that the tested analogues were not substrates for efflux pumps. Thus, efflux probably does not provide an explanation for the vexing problem contradicting on-

target versus whole-cell activity. Further, we assayed three analogues in the presence or absence of permeability-enhancing analogues ethambutol and thioridazine, which did not result in synergism, which would be indicative for permeability issues. Future studies might entail the quantification of compound accumulation³⁵⁻³⁷ to provide a definite answer on the conundrum of enzyme vs. whole-cell activity.

4. EXPERIMENTAL SECTION

4.1. CHEMISTRY

4.1.1. General

Solvents were purchased from standard commercial sources and of analytical grade. Building blocks and reagents were used as received without any further purification. TLC analysis was performed using pre-coated Alugram Silica Gel F254 plates from Machery-Nagel. Spots were examined under ultraviolet light at 254 nm. Column chromatography was carried out on a Reveleris X2 (Grace-Büchi) automated flash unit using the disposable silica gel cartridges. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 or DMSO-d_6 on a Varian Mercury 300/75 MHz spectrometer. Chemical shifts are given in parts per million (ppm δ), δ relative to residual solvent peak or TMS for ^1H and ^{13}C . Structural assignment was confirmed with ^1H - ^1H gCOSY, ^1H - ^{13}C gHSQC and ^1H - ^{13}C gHMBC. Exact mass measurements (HRMS) were performed on a Waters LCT Premier XETM Time of flight (TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSprayTM interface. Samples were infused in a $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (1:1) mixture at 100 $\mu\text{L}/\text{min}$. Preparative reversed phase HPLC chromatography was carried out using a Phenomenex Luna C-18 (21.2 \times 250 mm) column using a liner gradient from 10% MeCN to 100% MeCN in 10 mM ammonium bicarbonate solution over 20 min and at a flow rate of 17.5 mL/min. The purity of all final compounds was determined by LC-MS analyses on a Waters Alliance 2695 XE separation module using a Phenomenex Kinetex EVO C18, 5 μm 100 \times 2.1mm column and a gradient system of HCOOH in H_2O (0.1 %, v/v)/ HCOOH in CH_3CN (0.1 %, v/v) at a flow rate of 0.6 mL/min, 05:95 to 0:100 (5 to 100 % CH_3CN) in 8 minutes. All final compounds were shown to have a measured purity higher than 95 %.

cLogP values were calculated using ChemDraw Professional, version 15.0.0.106.

4.1.2. General procedure for the synthesis of final compounds

According a procedure in literature,¹¹ a suspension of compound 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione¹⁵ (1 eq), substituted aromatic aldehyde (1 – 2 eq) and sodium triacetoxyborohydride (1.5 – 4 eq) in dry 1,2-dichloroethane (~ 0.03 M) was stirred at room temperature under argon overnight or for 48 h. The reaction mixture was evaporated and dried with oil pump for 0.5 h. The residue was purified by column chromatography (10% ethyl acetate/hexane + 0.8 % Et₃N – 100% ethyl acetate + 0.8 % Et₃N or 100% CH₂Cl₂ - 10% MeOH/CH₂Cl₂ or 100% ethyl acetate – 5% MeOH/ethyl acetate in linear gradient elution) to afford pure intermediate. The intermediate was dissolved with 80% TFA/H₂O (~ 0.01 M), and L-cysteine hydrochloride (~ 0.27 M) was added to the reaction mixture. The reaction mixture was stirred at 72 °C for 5 h to 16 h. HRMS was used to monitor the reaction progress. Once the starting material was consumed completely, the reaction mixture was cooled to room temperature and evaporated. The residue was dissolved with the solvent mixture (1 – 2 mL, MeCN/*t*-BuOH/H₂O, v/v/v = 1/1/1 or acetic acid or H₂O) and purified with RP high-performance liquid chromatography (HPLC, Phenomenex Luna C-18, a liner gradient from 10% MeCN to 100% MeCN in H₂O over 20 min (10 mM ammonium bicarbonate) and a flow rate of 17.5 mL/min. After lyophilization, all final products were obtained as white powder.

5-Methyl-1-(1-((6-phenoxy)pyridin-2-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (3): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92 mg, 0.28 mmol), 6-phenoxyacetaldehyde **39** (110 mg, 0.56 mmol), sodium triacetoxyborohydride (120 mg, 0.56 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **3** (45 mg, 41%). ¹H NMR (300 MHz, DMSO-*d*₆) δ: 1.63 (d, *J* = 9.67 Hz, 2H), 1.74 - 1.95 (m, 5H), 2.06 - 2.20 (m, 2H), 2.91 (d, *J* = 11.72 Hz, 2H), 3.48 (s, 2H), 4.17 - 4.33 (m, 1H), 6.84 (d, *J* = 8.20 Hz, 1H), 7.07 - 7.15 (m, 2H), 7.16 - 7.24 (m, 2H), 7.36 - 7.47 (m, 2H), 7.64 (d, *J* = 1.17 Hz, 1H), 7.83 (dd, *J* = 8.05, 7.47 Hz, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 12.01, 30.01 (2C), 52.24, 52.39

(2C), 62.57, 108.90, 109.40, 117.58, 120.65 (2C), 124.27, 129.67 (2C), 137.69, 140.39, 150.80, 154.14, 157.52, 162.26, 163.65. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found 393.1924.

5-Methyl-1-(1-((4-phenoxy)pyridin-2-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (4):

Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (120 mg, 0.36 mmol), 4-phenoxybenzaldehyde **46** (70.8 mg, 0.360 mmol), sodium triacetoxyborohydride (113 mg, 0.530 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (32 mL) and L-cysteine hydrochloride (1.52 g, 8.64 mmol) was added to the reaction mixture to yield compound **4** (62 mg, 44%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.74 - 1.93 (m, 5H), 2.15 (t, *J* = 11.42 Hz, 2H), 2.93 (d, *J* = 11.42 Hz, 2H), 3.60 (s, 2H), 4.19 - 4.34 (m, 1H), 6.77 (dd, *J* = 5.56, 2.64 Hz, 1H), 7.03 (d, *J* = 2.64 Hz, 1H), 7.15 - 7.22 (m, 2H), 7.26 - 7.34 (m, 1H), 7.46 - 7.54 (m, 2H), 7.61 (d, *J* = 0.88 Hz, 1H), 8.37 (d, *J* = 5.56 Hz, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.01, 29.96 (2C), 52.22, 52.48 (2C), 62.98, 108.91, 110.43, 110.58, 120.50 (2C), 125.37, 130.44 (2C), 137.64, 150.72, 150.79, 153.79, 161.17, 163.65, 164.54. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found 393.1919.

5-Methyl-1-(1-((5-phenoxy)pyridin-3-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (5):

Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (98.0 mg, 0.298 mmol), 5-phenoxybenzaldehyde **51** (80.0 mg, 0.402 mmol), sodium triacetoxyborohydride (126 mg, 0.595 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **5** (52 mg, 44%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.67 Hz, 2H), 1.74 - 1.92 (m, 5H), 2.09 (t, *J* = 10.84 Hz, 2H), 2.90 (d, *J* = 10.84 Hz, 2H), 3.56 (s, 2H), 4.18 - 4.34 (m, 1H), 7.03 - 7.12 (m, 2H), 7.20 (tt, *J* = 7.43, 1.06 Hz, 1H), 7.34 - 7.39 (m, 1H), 7.40 - 7.48 (m, 2H), 7.63 (s, 1H), 8.27 (d, *J* = 1.76 Hz, 1H), 8.33 (s, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.98, 29.89 (2C),

52.21 (3C), 58.13, 108.91, 118.58 (2C), 124.04, 125.69, 130.27 (2C), 135.47, 137.66, 139.55, 144.91, 150.79, 153.06, 156.11, 163.65. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found 393.1928.

5-Methyl-1-(1-((2-phenoxy)pyridin-4-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (6):

Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (110 mg, 0.33 mmol), 2-phenoxyisonicotinaldehyde **43** (80 mg, 0.40 mmol), sodium triacetoxyborohydride (106 mg, 0.50 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **6** (56 mg, 43%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.67 (d, *J* = 9.37 Hz, 2H), 1.76 - 1.99 (m, 5H), 2.07 - 2.20 (m, 2H), 2.92 (d, *J* = 11.42 Hz, 2H), 3.56 (s, 2H), 4.20 - 4.37 (m, 1H), 6.99 (s, 1H), 7.05 - 7.15 (m, 3H), 7.17 - 7.25 (m, 1H), 7.36 - 7.46 (m, 2H), 7.66 (d, *J* = 1.17 Hz, 1H), 8.08 (d, *J* = 5.27 Hz, 1H), 11.10 (br. s., 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.00, 29.99 (2C), 52.19, 52.43 (2C), 60.02, 108.94, 110.72, 119.07, 121.11 (2C), 124.36, 129.61 (2C), 137.67, 147.15, 150.82, 152.39, 153.99, 163.36, 163.67. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found 393.1927.

5-Methyl-1-(1-(3-(pyridin-2-yloxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (7):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (148.2 mg, 0.45 mmol), 3-(pyridin-2-yloxy)benzaldehyde **62** (134 mg, 0.675 mmol), sodium triacetoxyborohydride (190 mg, 0.90 mmol) in dry 1,2-dichloroethane (15 mL) using methanol - CH₂Cl₂ eluent system to obtain the intermediate, which was dissolved with TFA (15 mL) and yielded compound **7** (130 mg, 74%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.96 Hz, 2H), 1.73 - 1.94 (m, 5H), 1.98 - 2.16 (m, 2H), 2.93 (d, *J* = 11.13 Hz, 2H), 3.52 (br. s., 2H), 4.27 (ddd, *J* = 11.94, 8.13, 3.95 Hz, 1H), 6.93 - 7.22 (m, 5H), 7.32 - 7.41 (m, 1H), 7.65 (s, 1H), 7.85 (ddd, *J* = 8.35, 7.18, 2.05 Hz, 1H), 8.16 (ddd, *J* = 4.98, 2.05, 0.88 Hz, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.95, 29.96 (2C), 52.30 (3C), 61.15, 108.90, 111.48, 119.00, 119.63, 121.05, 124.73,

129.34, 137.67, 140.15, 140.57, 147.46, 150.78, 153.90, 163.01, 163.64. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found, 393.1922.

5-Methyl-1-(1-(3-(pyridin-3-yloxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (8):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (126 mg, 0.384 mmol), 3-(pyridin-3-yloxy)benzaldehyde **63** (153 mg, 0.768 mmol), sodium triacetoxyborohydride (163 mg, 0.768 mmol) in dry 1,2-dichloroethane (10 mL) using methanol - CH_2Cl_2 eluent system to obtain the intermediate, which was dissolved with TFA (15 mL) and yielded compound **8** (69 mg, 46%). 1H NMR (300 MHz, DMSO- d_6) δ : 1.64 (d, $J = 9.67$ Hz, 2H), 1.73 - 1.93 (m, 5H), 1.97 - 2.14 (m, 2H), 2.91 (d, $J = 11.72$ Hz, 2H), 3.51 (s, 2H), 4.26 (tt, $J = 12.05, 3.92$ Hz, 1H), 6.94 (dt, $J = 8.13, 1.21$ Hz, 1H), 7.01 - 7.07 (m, 1H), 7.14 (d, $J = 7.91$ Hz, 1H), 7.32 - 7.47 (m, 3H), 7.64 (d, $J = 1.17$ Hz, 1H), 8.38 (br. s., 2H), 11.19 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.97, 29.97 (2C), 52.30 (3C), 61.11, 108.90, 117.15, 118.72, 124.41, 124.72 (br. s., 1C) 125.50, 129.95, 137.66, 140.79, 141.25, 144.46, 150.79, 155.98 (2C), 163.64. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 398.1921; found, 393.1939.

5-Methyl-1-(1-(3-(pyridin-4-yloxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (9):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (148 mg, 0.45 mmol), 3-(pyridin-4-yloxy)benzaldehyde **64** (135 mg, 0.675 mmol), sodium triacetoxyborohydride (191 mg, 0.90 mmol) in dry 1,2-dichloroethane (15 mL) using methanol - CH_2Cl_2 eluent system to obtain the intermediate, which was dissolved with TFA (10 mL) and yielded compound **9** (45 mg, 26%). 1H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J = 9.37$ Hz, 2H), 1.73 - 1.95 (m, 5H), 2.00 - 2.15 (m, 2H), 2.92 (d, $J = 11.13$ Hz, 2H), 3.55 (s, 2H), 4.27 (ddd, $J = 11.94, 7.98, 4.10$ Hz, 1H), 6.93 (d, $J = 3.22$ Hz, 2H), 7.04 - 7.10 (m, 1H), 7.10 - 7.15 (m, 1H), 7.25 (d, $J = 7.62$ Hz, 1H), 7.40 - 7.49 (m, 1H), 7.65 (d, $J = 1.17$ Hz, 1H), 8.49 (br. s., 2H), 11.19 (br. s., 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.96, 29.97 (2C), 52.29 (3C), 60.96, 108.89, 112.06 (br. s. 2C),

119.12, 120.47, 125.73, 130.17, 137.68, 141.51, 150.79 (2C), 151.54, 153.55, 163.64, 163.98. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_3 + H]^+$, 393.1921; found, 393.1910.

1-(1-(3-(Cyclopentyloxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (10):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (131 mg, 0.399 mmol), 3-(cyclopentyloxy)benzaldehyde **66** (114 mg, 0.598 mmol), sodium triacetoxyborohydride (127 mg, 0.598 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (10 mL) and yielded compound **10** (86 mg, 56%). 1H NMR (300 MHz, DMSO- d_6) δ : 1.54 - 2.11 (m, 17H), 2.92 (d, $J = 10.84$ Hz, 2H), 3.46 (s., 2H), 4.16 - 4.34 (m, 1H), 4.73 - 4.84 (m, 1H), 6.74 - 6.89 (m, 3H), 7.16 - 7.26 (m, 1H), 7.65 (s, 1H), 11.19 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 12.00, 23.60 (2C), 29.98 (2C), 32.27 (2C), 52.33 (3C), 61.58 (1C), 78.38, 108.90, 113.51, 115.89, 120.59, 129.12, 137.69, 140.01 (br. s., 1C), 150.80, 157.58, 163.67. HRMS (ESI): calculated for $[C_{22}H_{29}N_3O_3 + H]^+$, 384.2282; found, 384.2280.

1-(1-(3-(Cyclohexyloxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (11):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (132 mg, 0.400 mmol), 3-(cyclohexyloxy)benzaldehyde **68** (123 mg, 0.600 mmol), sodium triacetoxyborohydride (127 mg, 0.600 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (10 mL) and yielded compound **11** (50.4 mg, 32%). 1H NMR (300 MHz, DMSO- d_6) δ : 1.19 - 1.79 (m, 14H), 1.79 - 1.97 (m, 4H), 1.97 - 2.15 (m, 2H), 2.91 (d, $J = 11.13$ Hz, 2H), 3.46 (s, 2H), 4.17 - 4.40 (m, 2H), 6.76 - 6.90 (m, 3H), 7.16 - 7.25 (m, 1H), 7.65 (d, $J = 0.88$ Hz, 1H), 11.20 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.74, 22.88 (2C), 24.90, 29.75 (2C), 31.08 (2C), 52.08 (2C), 52.14, 61.32, 73.81, 108.67, 113.57, 116.07, 120.50, 128.91, 137.44, 139.84, 150.56, 156.98, 163.41. HRMS (ESI): calculated for $[C_{23}H_{31}N_3O_3 + H]^+$, 398.2438; found, 398.2435.

1-(1-(3-(4-Chlorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (12):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (120.0 mg, 0.364 mmol), 3-(4-chlorophenoxy)benzaldehyde **73** (169 mg, 0.728 mmol), sodium triacetoxyborohydride (154 mg, 0.728 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (15 mL) and yielded compound **12** (80.0 mg, 52%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.72 - 1.95 (m, 5H), 1.98 - 2.16 (m, 2H), 2.91 (d, *J* = 11.13 Hz, 2H), 3.51 (s, 2H), 4.26 (ddd, *J* = 11.86, 8.05, 4.10 Hz, 1H), 6.92 (dd, *J* = 8.20, 1.76 Hz, 1H), 6.98 - 7.07 (m, 3H), 7.12 (d, *J* = 7.62 Hz, 1H), 7.31 - 7.40 (m, 1H), 7.40 - 7.48 (m, 2H), 7.64 (s, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.98, 29.96 (2C), 52.30 (3C), 61.14, 108.91, 117.37, 118.93, 120.04 (2C), 124.26, 127.05, 129.87 (3C), 137.66, 141.14, 150.80, 155.78, 156.16, 163.65. HRMS (ESI): calculated for [C₂₃H₂₄ClN₃O₃ + H]⁺, 426.1579; found, 426.1597.

1-(1-(3-(4-Methoxyphenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (13):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (153 mg, 0.465 mmol), 3-(4-methoxyphenoxy)benzaldehyde **74** (159 mg, 0.700 mmol), sodium triacetoxyborohydride (197 mg, 0.93 mmol) in dry 1,2-dichloroethane (15 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (10 mL) and yielded compound **13** (90.3 mg, 46%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.58 - 1.70 (m, 2H), 1.72 - 1.91 (m, 5H), 1.98 - 2.10 (m, 2H), 2.89 (d, *J* = 11.42 Hz, 2H), 3.46 (s, 2H), 3.75 (s, 3H), 4.17 - 4.34 (m, 1H), 6.78 (ddd, *J* = 8.05, 2.49, 0.88 Hz, 1H), 6.89 - 6.92 (m, 1H), 6.93 - 7.05 (m, 5H), 7.28 (t, *J* = 7.91 Hz, 1H), 7.63 (d, *J* = 1.17 Hz, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.97, 29.97 (2C), 52.32 (3C), 55.39, 61.31, 108.90, 115.06 (2C), 115.76, 117.45, 120.58 (2C), 122.95, 129.54, 137.65, 140.72, 149.42, 150.79, 155.55, 157.97, 163.64. HRMS (ESI): calculated for [C₂₄H₂₇N₃O₄ + H]⁺, 422.2074; found, 422.2055.

5-Methyl-1-(1-(3-(*p*-tolxyloxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (14): Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (114 mg, 0.34 mmol), 3-(*p*-tolxyloxy)benzaldehyde **75** (146 mg, 0.69 mmol), sodium triacetoxyborohydride (146 mg, 0.69 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (15 mL) and yielded compound **14** (45.4 mg, 79%). ¹H NMR (300 MHz, DMSO-*d*₆) δ: 1.64 (d, *J* = 10.25 Hz, 2H), 1.72 - 1.92 (m, 5H), 2.04 (t, *J* = 10.98 Hz, 2H), 2.29 (s, 3H), 2.90 (d, *J* = 10.84 Hz, 2H), 3.48 (s, 2H), 4.17 - 4.33 (m, 1H), 6.84 (d, *J* = 7.91 Hz, 1H), 6.87 - 6.97 (m, 3H), 7.05 (d, *J* = 7.62 Hz, 1H), 7.19 (d, *J* = 8.20 Hz, 2H), 7.26 - 7.36 (m, 1H), 7.64 (s, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 11.97, 20.23, 29.97 (2C), 52.30 (3C), 61.26, 108.90, 116.58, 118.22, 118.73, 123.41, 129.62, 130.38 (2C), 132.53, 137.66, 140.82, 150.79, 154.21, 157.14, 163.64. HRMS (ESI): calculated for [C₂₄H₂₇N₃O₃ + H]⁺, 406.2125; found, 406.2116.

1-(1-(3-(3,4-Dichlorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (15): Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (152 mg, 0.460 mmol), 3-(3,4-dichlorophenoxy)benzaldehyde **76** (184 mg, 0.690 mmol), sodium triacetoxyborohydride (195 mg, 0.920 mmol) in dry 1,2-dichloroethane (15 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (15 mL) and yielded compound **15** (64.5 mg, 31%). ¹H NMR (300 MHz, DMSO-*d*₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.72 - 1.94 (m, 5H), 1.99 - 2.15 (m, 2H), 2.91 (d, *J* = 11.42 Hz, 2H), 3.52 (s, 2H), 4.26 (ddd, *J* = 11.94, 7.98, 4.10 Hz, 1H), 6.95 - 7.03 (m, 2H), 7.04 - 7.08 (m, 1H), 7.17 (d, *J* = 7.62 Hz, 1H), 7.29 (d, *J* = 2.64 Hz, 1H), 7.35 - 7.43 (m, 1H), 7.59 - 7.67 (m, 2H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ: 11.98, 29.99 (2C), 52.28 (3C), 61.03, 108.91, 117.77, 118.45, 119.26, 120.04, 124.82, 125.16, 130.03, 131.60, 131.98, 137.66, 141.32, 150.80, 155.50, 156.56, 163.65. HRMS (ESI): calculated for [C₂₃H₂₃Cl₂N₃O₃ + H]⁺, 460.1189; found, 460.1178.

1-(1-(3-(3-Chlorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (16):

Following the general procedure for the synthesis of final compounds (method 1): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (100.0 mg, 0.300 mmol), 3-(3-chlorophenoxy)benzaldehyde **77** (141 mg, 0.600 mmol), sodium triacetoxyborohydride (127 mg, 0.600 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with TFA (10 mL) and yielded compound **16** (63 mg, 50%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.73 - 1.94 (m, 5H), 1.99 - 2.14 (m, 2H), 2.91 (d, *J* = 10.54 Hz, 2H), 3.52 (s, 2H), 4.17 - 4.35 (m, 1H), 6.96 (dd, *J* = 8.20, 2.05 Hz, 2H), 7.05 (d, *J* = 1.76 Hz, 2H), 7.12 - 7.23 (m, 2H), 7.34 - 7.45 (m, 2H), 7.64 (s, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.01, 29.98 (2C), 52.30 (3C), 61.10, 108.96, 116.82, 117.86, 118.07, 119.37, 123.19, 124.71, 130.03, 131.52, 133.98, 137.69, 141.21, 150.83, 155.69, 158.04, 163.70. HRMS (ESI): calculated for [C₂₃H₂₄ClN₃O₃ + H]⁺, 426.1579; found, 426.1578.

5-Methyl-1-(1-(3-(*m*-tolylloxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (17): Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (165 mg, 0.500 mmol), 3-(*m*-tolylloxy)benzaldehyde **78** (212 mg, 1.00 mmol), sodium triacetoxyborohydride (212 mg, 1.00 mmol) in dry 1,2-dichloroethane (15 mL) using ethyl acetate - hexane eluent system to obtain the intermediate as colorless gel (220.0 mg, 83.7%). The obtained intermediate (120 mg, 0.228 mmol) was dissolved with 80% TFA/H₂O (24 mL) and L-cysteine hydrochloride (1.02 g, 6.48 mmol) was added to the reaction mixture to yield compound **17** (72.0 mg, 78%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.64 (d, *J* = 9.37 Hz, 2H), 1.73 - 1.92 (m, 5H), 1.99 - 2.12 (m, 2H), 2.29 (s, 3H), 2.91 (d, *J* = 11.42 Hz, 2H), 3.49 (s, 2H), 4.18 - 4.34 (m, 1H), 6.75 - 6.90 (m, 3H), 6.92 - 7.01 (m, 2H), 7.08 (d, *J* = 7.91 Hz, 1H), 7.26 (t, *J* = 7.91 Hz, 1H), 7.30 - 7.37 (m, 1H), 7.64 (d, *J* = 1.17 Hz, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.98, 20.93, 29.98 (2C), 52.31 (3C), 61.23, 108.90, 115.51, 117.10, 118.71, 118.99, 123.72, 124.06, 129.69, 129.74, 137.67, 139.70, 140.88, 150.80, 156.63, 156.69, 163.65. HRMS (ESI): calculated for [C₂₄H₂₇N₃O₃ + H]⁺, 406.2125; found, 406.2127.

1-(1-(3-(3-Fluorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (18):

Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 3-(3-fluorophenoxy)benzaldehyde **84** (121 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **18** (58.7 mg, 51%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.73 - 1.93 (m, 5H), 1.99 - 2.13 (m, 2H), 2.91 (d, *J* = 11.42 Hz, 2H), 3.51 (s, 2H), 4.17 - 4.34 (m, 1H), 6.78 - 6.89 (m, 2H), 6.92 - 7.01 (m, 2H), 7.02 - 7.07 (m, 1H), 7.15 (d, *J* = 7.62 Hz, 1H), 7.34 - 7.46 (m, 2H), 7.64 (d, *J* = 1.17 Hz, 1H), 11.19 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.98, 29.99 (2C), 52.31 (3C), 61.10, 105.65 (d, *J*_{CF} = 25.50 Hz), 108.90, 109.91 (d, *J*_{CF} = 21.80 Hz), 113.97 (d, *J*_{CF} = 2.30 Hz), 117.74, 119.26, 124.55, 129.92, 131.32 (d, *J*_{CF} = 9.00 Hz), 137.67, 141.21, 150.80, 155.69, 158.40 (d, *J*_{CF} = 11.52 Hz), 162.87 (d, *J*_{CF} = 243.80 Hz), 163.65, several signals overlapped. ¹⁹F NMR (282 MHz, DMSO-d₆) δ: -111.02 - -110.90 (m). HRMS (ESI): calculated for [C₂₃H₂₄FN₃O₃ + H]⁺, 410.1874; found 410.1881.

1-(1-(3-(3-Hydroxyphenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (19):

Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (132 mg, 0.400 mmol), 3-bromobenzaldehyde **80** (148 mg, 0.800 mmol), sodium triacetoxyborohydride (169 mg, 0.800 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate **81** (106 mg, 53%). According to a modified literature procedure,¹⁸ the suspension of the intermediate **81** (106 mg, 0.213 mmol), **83** (240 mg, 1.07 mmol), K₃PO₄ (158 mg, 0.746 mmol), picolinic acid (9.2 mg, 0.075 mmol) and CuI (8.1 mg, 0.043 mmol) in dry DMSO (3 mL) yielded the intermediate, which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **19** (21 mg, 24%). ¹H NMR (300 MHz, CDCl₃) δ: 1.65 (d, *J* = 9.96 Hz, 2H), 1.72 - 1.92 (m, 5H), 2.07 (s, 2H), 2.92 (d,

$J = 10.54$ Hz, 2H), 3.51 (s, 2H), 4.19 - 4.34 (m, 1H), 6.34 - 6.38 (m, 1H), 6.41 (m, 1H), 6.52 (m, 1H), 6.90 (dd, $J = 8.05$, 1.90 Hz, 1H), 7.00 (s, 1H), 7.09 (d, $J = 7.62$ Hz, 1H), 7.15 (t, $J = 8.20$ Hz, 1H), 7.34 (t, $J = 9.00$ Hz, 1H), 7.63 (s, 1H), 9.58 (s, 1H), 11.19 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 12.00, 29.93 (2C), 52.28 (3C), 61.17, 105.33, 108.82, 108.93, 110.43, 117.55, 119.07, 123.93, 129.70, 130.41, 137.67, 141.30 (1C, it cannot be found from CNMR, but can be observed in the ^1H - ^{13}C gHMBC spectrum), 150.80, 156.40, 157.98, 158.81, 163.67.

1-(1-(3-(3-Methoxyphenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (20):

Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (148 mg, 0.450 mmol), 3-(3-methoxyphenoxy)benzaldehyde **79** (205 mg, 0.900 mmol), sodium triacetoxyborohydride (191 mg, 0.900 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate, which was dissolved with 80% TFA/ H_2O (40 mL) and L-cysteine hydrochloride (1.70 g, 10.8 mmol) was added to the reaction mixture to yield compound **20** (70.0 mg, 37%). ^1H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J = 10.25$ Hz, 2H), 1.73 - 1.93 (m, 5H), 1.96 - 2.17 (m, 2H), 2.92 (d, $J = 8.79$ Hz, 2H), 3.40 - 3.60 (m, 2H), 3.73 (s, 3 H), 4.19 - 4.35 (m, 1H), 6.49 - 6.60 (m, 2H), 6.72 (ddd, $J = 8.35$, 2.34, 0.73 Hz, 1H), 6.91 (d, $J = 8.20$ Hz, 1H), 7.01 (br. s., 1H), 7.10 (d, $J = 7.62$ Hz, 1H), 7.28 (t, $J = 8.20$ Hz, 1H), 7.31 - 7.40 (m, 1H), 7.63 (br. s., 1H), 11.20 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.89, 29.86 (2C), 52.13 - 52.13 (3C), 55.15, 61.07, 104.37, 108.82, 108.90, 110.24, 117.28, 118.82, 123.90, 129.66, 130.41, 137.57, 140.80, 150.69, 156.25, 157.84, 160.59, 163.56. HRMS (ESI): calculated for $[\text{C}_{24}\text{H}_{27}\text{N}_3\text{O}_4 + \text{H}]^+$, 422.2074; found, 422.2092.

1-(1-(3-(4-Chloro-3-(trifluoromethyl)phenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-

2,4(1H,3H)-dione (21): Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92 mg, 0.28 mmol), 3-(4-chloro-3-(trifluoromethyl)phenoxy)benzaldehyde **85** (168 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane

eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **21** (73.5 mg, 53%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.64 (d, *J* = 9.37 Hz, 2H), 1.73 - 1.93 (m, 5H), 2.00 - 2.14 (m, 2H), 2.91 (d, *J* = 11.42 Hz, 2H), 3.53 (s, 2H), 4.26 (m, 1H), 7.02 (ddd, *J* = 8.05, 2.49, 0.88 Hz, 1H), 7.07 - 7.11 (m, 1H), 7.19 (d, *J* = 7.62 Hz, 1H), 7.29 (dd, *J* = 8.79, 3.22 Hz, 1H), 7.38 - 7.46 (m, 2H), 7.62 (d, *J* = 1.17 Hz, 1H), 7.72 (d, *J* = 8.79 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.00, 29.99 (2C), 52.27 (3C), 61.01, 108.93, 117.21 (q, *J*_{CF} = 5.30 Hz), 117.97, 119.45, 120.56, 123.19, 124.19, 125.11, 127.90 (q, *J*_{CF} = 31.30 Hz), 130.16, 133.41, 137.63, 141.43, 150.83, 155.24, 156.17, 163.70, several signals overlapped or could not be found. ¹⁹F NMR (282 MHz, DMSO-d₆) δ: -61.68. HRMS (ESI): calculated for [C₂₄H₂₃ClF₃N₃O₃ + H]⁺, 494.1453; found 494.1460.

1-(1-(3-(3,4-Difluorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (22):
Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 3-(3,4-difluorophenoxy)benzaldehyde **86** (131 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **22** (75.6 mg, 63%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.63 (d, *J* = 9.67 Hz, 2H), 1.72 - 1.90 (m, 5H), 1.98 - 2.12 (m, 2H), 2.90 (d, *J* = 11.72 Hz, 2H), 3.49 (s, 2H), 4.17 - 4.32 (m, 1H), 6.79 - 6.87 (m, 1H), 6.87 - 6.93 (m, 1H), 6.99 - 7.03 (m, 1H), 7.12 (d, *J* = 7.62 Hz, 1H), 7.18 (ddd, *J* = 11.72, 6.74, 2.93 Hz, 1H), 7.32 - 7.39 (m, 1H), 7.45 (dt, *J* = 10.54, 9.23 Hz, 1H), 7.63 (d, *J* = 1.17 Hz, 1H), 11.18 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.97, 29.99 (2C), 52.31 (3C), 61.10, 108.30 - 109.57 (m), 108.91, 114.84 (dd, *J*_{CF} = 6.91, 3.45 Hz), 117.07, 118.16 (d, *J*_{CF} = 18.43 Hz), 118.70, 124.30, 129.89, 137.67, 141.20, 145.75 (dd, *J*_{CF} = 239.30, 12.80 Hz), 149.72 (dd, *J*_{CF} = 246.00, 15.00 Hz), 150.80, 153.07 (dd, *J*_{CF} = 8.06, 2.30 Hz), 156.25, 163.67, several signals overlapped or

could not be found. ^{19}F NMR (282 MHz, DMSO- d_6) δ : -145.33 - 145.07 (m), -135.46 - 135.20 (m). HRMS (ESI): calculated for $[\text{C}_{23}\text{H}_{23}\text{F}_2\text{N}_3\text{O}_3 + \text{H}]^+$, 428.1780; found, 428.1773.

5-Methyl-1-(1-(3-(3-(trifluoromethyl)phenoxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (23): Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 3-(3-(trifluoromethyl)phenoxy)benzaldehyde **87** (149 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/ H_2O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **23** (84.1 mg, 65%). ^1H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J=9.67$ Hz, 2H), 1.73 - 1.91 (m, 5H), 1.99 - 2.15 (m, 2H), 2.92 (d, $J=11.13$ Hz, 2H), 3.53 (s, 2H), 4.26 (t, $J=12.01$ Hz, 1H), 6.99 (dd, $J=8.05, 1.90$ Hz, 1H), 7.07 (s, 1H), 7.18 (d, $J=7.32$ Hz, 1H), 7.25 - 7.34 (m, 2H), 7.36 - 7.44 (m, 1H), 7.49 (d, $J=7.91$ Hz, 1H), 7.58 - 7.68 (m, 2H) 11.20 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.98, 29.95 (2C), 52.27 (3C), 61.04, 108.93, 114.33 (q, $J_{\text{CF}}=3.40$ Hz), 117.95, 119.48, 119.68 (q, $J_{\text{CF}}=3.40$ Hz), 121.97, 124.88, 125.54, 130.10, 130.69 (d, $J_{\text{CF}}=31.5$ Hz) 131.45, 137.64, 141.26, 150.80, 155.46, 157.59, 163.67, several signals overlapped or could not be found. ^{19}F NMR (282 MHz, DMSO- d_6) δ : -61.27. HRMS (ESI): calculated for $[\text{C}_{24}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_3 + \text{H}]^+$, 460.1843; found, 460.1837.

5-Methyl-1-(1-(3-(3-(trifluoromethoxy)phenoxy)benzyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (24): Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (49.4 mg, 0.150 mmol), 3-(3-(trifluoromethoxy)phenoxy)benzaldehyde **88** (84.7 mg, 0.300 mmol), sodium triacetoxyborohydride (63.6 mg, 0.300 mmol) in dry 1,2-dichloroethane (6 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/ H_2O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **24** (30.3 mg, 42%). ^1H NMR (300 MHz, DMSO- d_6) δ : 1.64 (d, $J=9.37$ Hz, 2H), 1.74 - 1.92 (m, 5H), 2.00 - 2.12 (m, 2H), 2.91 (d, $J=12.01$

Hz, 2H), 3.52 (s, 2H), 4.18 - 4.34 (m, 1H), 6.95 - 7.03 (m, 3H), 7.05 - 7.08 (m, 1H), 7.09 - 7.15 (m, 1H), 7.17 (d, $J = 7.62$ Hz, 1H), 7.36 - 7.43 (m, 1H), 7.47 - 7.55 (m, 1H), 7.63 (d, $J = 1.17$ Hz, 1H), 11.19 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.97, 29.98 (2C), 52.28 (3C), 61.07, 108.91, 110.79, 115.26, 116.74, 117.92, 119.45, 119.96 (q, $J_{CF} = 255.00$ Hz) 124.82, 130.03, 131.51, 137.63, 141.29, 149.23, 150.80, 155.40, 158.33, 163.65. ^{19}F NMR (282 MHz, DMSO- d_6) δ : -56.86. HRMS (ESI): calculated for $[\text{C}_{24}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_4 + \text{H}]^+$, 476.1792; found 476.1810.

1-(1-(3-(3,5-Dichlorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (25):

Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 3-(3,5-dichlorophenoxy)benzaldehyde **89** (150 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/ H_2O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **25** (85.4 mg, 66%). ^1H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J = 9.08$ Hz, 2H), 1.73 - 1.94 (m, 5H), 2.00 - 2.14 (m, 2H), 2.91 (d, $J = 11.42$ Hz, 2H), 3.53 (s, 2H), 4.20 - 4.33 (m, 1H), 6.99 - 7.05 (m, 3H), 7.07 - 7.11 (m, 1H), 7.19 (d, $J = 7.91$ Hz, 1H), 7.36 (t, $J = 1.90$ Hz, 1H), 7.41 (t, $J = 7.50$ Hz, 1H), 7.64 (d, $J = 1.17$ Hz, 1H), 11.19 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.98, 29.99 (2C), 52.28 (3C), 60.98, 108.91, 116.81 (2C), 118.16, 119.63, 122.79, 125.23, 130.15, 134.94 (2C), 137.66, 141.43, 150.80, 154.92, 158.75, 163.65. HRMS (ESI): calculated for $[\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}_3 + \text{H}]^+$, 460.1189; found 460.1191.

1-(1-(3-(3,5-Difluorophenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (26):

Following the general procedure for the synthesis of final compounds (method 2): 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 3-(3,5-difluorophenoxy)benzaldehyde **90** (131 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/ H_2O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1

mmol) was added to the reaction mixture to yield compound **26** (65.8 mg, 57%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.96 Hz, 2H), 1.73 - 1.94 (m, 5H), 2.00 - 2.13 (m, 2H), 2.92 (d, *J* = 11.42 Hz, 2H), 3.53 (s, 2H), 4.27 (m, 1H), 6.65 - 6.77 (m, 2H), 6.94 - 7.04 (m, 2H), 7.07 - 7.12 (m, 1H), 7.20 (d, *J* = 7.62 Hz, 1H), 7.37 - 7.45 (m, 1H), 7.64 (d, *J* = 1.17 Hz, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 11.98, 29.99 (2C), 52.30 (3C), 61.03, 98.63 (t, *J*_{CF} = 26.30 Hz, 2C), 101.67 (dd, *J*_{CF} = 19.50, 9.00 Hz), 108.91, 118.16, 119.66, 125.17, 130.07, 137.66, 141.43, 150.80, 154.88, 159.36 (t, *J*_{CF} = 14.30 Hz), 163.07 (dd, *J*_{CF} = 243.80, 15.30 Hz, 2C), 163.65, several signals overlapped. ¹⁹F NMR (282 MHz, DMSO-d₆) δ: -108.41 - 108.14 (m). HRMS (ESI): calculated for [C₂₃H₂₃F₂N₃O₃ + H]⁺, 428.1780; found 428.1786.

1-(1-(3-(3,5-Bis(trifluoromethyl)phenoxy)benzyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (27): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (86.2 mg, 0.260 mmol), 3-(3,5-bis(trifluoromethyl)phenoxy)benzaldehyde **91** (167 mg, 0.500 mmol), sodium triacetoxyborohydride (110 mg, 0.520 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (32 mL) and L-cysteine hydrochloride (1.4 g, 8.9 mmol) was added to the reaction mixture to yield compound **27** (43.0 mg, 31%). ¹H NMR (300 MHz, CD₃OD) δ: 1.76 - 1.97 (m, 7H), 2.19 (td, *J* = 11.86, 2.34 Hz, 2H), 3.03 (d, *J* = 11.72 Hz, 2H), 3.60 (s, 2H), 4.33 - 4.45 (m, 1H), 7.06 (ddd, *J* = 8.05, 2.49, 0.88 Hz, 2H), 7.15 - 7.18 (m, 1H), 7.27 (d, *J* = 7.91 Hz, 1H), 7.42 - 7.49 (m, 4H), 7.67 (s, 1H). ¹³C NMR (75 MHz, CD₃OD) δ: 10.87, 29.84 (2C), 52.36 (2C), 53.10, 61.47, 110.06, 115.54 - 115.69 (m), 117.57 (d, *J*_{CF} = 3.46 Hz, 2C), 124.82 (q, *J*_{CF} = 270.00 Hz, 2C), 118.64, 120.25, 125.99, 130.08, 132.96 (q, *J*_{CF} = 33.80 Hz, 2C), 137.62, 140.92, 151.41, 155.16, 159.24, 164.84, several signals overlapped or cannot be found. ¹⁹F NMR (282 MHz, CD₃OD) δ: -64.58. HRMS (ESI): calculated for [C₂₅H₂₃F₆N₃O₃ + H]⁺, 528.1716; found 528.1718.

1-(1-((6-(4-Hydroxyphenoxy)pyridin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (28): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (86.6 mg, 0.263 mmol), 6-(4-

hydroxyphenoxy)picolinaldehyde **94** (85.0 mg, 0.395 mmol), sodium triacetoxyborohydride (111 mg, 0.526 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - methanol eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **28** (54.8 mg, 51%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.64 (d, *J* = 9.37 Hz, 2H), 1.74 - 1.94 (m, 5H), 2.13 (t, *J* = 11.13 Hz, 2H), 2.92 (d, *J* = 11.13 Hz, 2H), 3.47 (s, 2H), 4.17 - 4.33 (m, 1H), 6.70 (d, *J* = 9.00 Hz, 1H), 6.74 - 6.81 (m, 2H), 6.89 - 6.97 (m, 2H), 7.13 (d, *J* = 9.00 Hz, 1H), 7.65 (s, 1H), 7.76 (t, *J* = 9.00 Hz, 1H), 9.34 (s, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.01, 29.99 (2C), 52.25, 52.46 (2C), 62.68, 108.36, 108.91, 115.87 (2C), 116.85, 122.03 (2C), 137.69, 140.10, 145.89, 150.80, 154.16, 157.35, 163.18, 163.67. HRMS (ESI): calculated for [C₂₂H₂₄N₄O₄ + H]⁺, 409.1870; found 409.1874.

2-((6-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)pyridin-2-yl)oxy)benzoic acid (29) Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (116 mg, 0.352 mmol), methyl 2-((6-formylpyridin-2-yl)oxy)benzoate **96** (125 mg, 0.488 mmol), sodium triacetoxyborohydride (207 mg, 0.975 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - methanol eluent system to obtain the picolinate intermediate, which was dissolved in THF (8 mL). NaOH (141 mg, 3.52 mmol) in H₂O (4 mL) was added to the reaction mixture at room temperature. The solution was stirred at room temperature for 2 days and 2 M aq. HCl was used to adjust the pH to 3. The suspension was concentrated to offer the picolinic acid intermediate, which was dissolved with 80% TFA/H₂O (32 mL) and L-cysteine hydrochloride (1.36 g, 8.64 mmol) was added to the reaction mixture to yield compound **29** (82.4 mg, 54%). ¹H NMR (300 MHz, D₂O) δ: 1.81 - 2.03 (m, 7H), 3.00 - 3.17 (m, 2H), 3.48 (d, *J* = 12.59 Hz, 2H), 4.21 (s, 2H), 4.47 - 4.60 (m, 1H), 6.98 (d, *J* = 8.20 Hz, 1H), 7.05 (d, *J* = 7.32 Hz, 1H), 7.12 (dd, *J* = 8.05, 1.03 Hz, 1H), 7.26 (td, *J* = 7.62, 1.17 Hz, 1H), 7.34 (d, *J* = 0.88 Hz, 1H), 7.43 (td, *J* = 7.76, 1.76 Hz, 1H), 7.56 (dd, *J* = 7.62, 1.76 Hz, 1H), 7.79 (dd, *J* = 8.35, 7.47 Hz, 1H). ¹³C NMR (75 MHz, D₂O) δ: 11.35, 27.02 (2C), 50.65 (2C), 52.07, 59.09, 111.29, 111.87, 118.71, 122.60, 125.52, 128.79, 130.86, 132.91, 138.42, 141.52,

146.60, 149.59, 151.91, 163.25, 166.29, 174.75. HRMS (ESI): calculated for $[C_{22}H_{24}N_4O_5 + H]^+$, 437.1819; found 437.1821.

1-(1-((6-(3-Chlorophenoxy)pyridin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (30): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (92.2 mg, 0.280 mmol), 6-(3-chlorophenoxy)picolinaldehyde **40** (130 mg, 0.560 mmol), sodium triacetoxyborohydride (119 mg, 0.560 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **30** (50.2 mg, 42%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.63 (d, *J* = 9.08 Hz, 2H), 1.74 - 1.95 (m, 5H), 2.08 - 2.23 (m, 2H), 2.92 (d, *J* = 11.13 Hz, 2H), 3.50 (s, 2H), 4.25 (m, 1H), 6.93 (d, *J* = 7.62 Hz, 1H), 7.10 (m, 1H), 7.19 - 7.30 (m, 3H), 7.39 - 7.48 (m, 1H), 7.63 (d, *J* = 0.88 Hz, 1H), 7.82 - 7.91 (m, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.01, 30.01 (2C), 52.21, 52.33 (2C), 62.43, 108.91, 109.86, 118.24, 119.48, 120.84, 124.26, 131.02, 133.46, 137.64, 140.67, 150.79, 154.97, 157.41, 161.65, 163.65. HRMS (ESI): calculated for $[C_{22}H_{23}ClN_4O_3 + H]^+$, 427.1531; found 427.1552.

1-(1-((4-(3-Chlorophenoxy)pyridin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (31): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (96.5 mg, 0.290 mmol), 4-(3-chlorophenoxy)picolinaldehyde **47** (90.0 mg, 0.390 mmol), sodium triacetoxyborohydride (93.1 mg, 0.440 mmol) in dry 1,2-dichloroethane (10 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (32 mL) and L-cysteine hydrochloride (1.52 g, 8.64 mmol) was added to the reaction mixture to yield compound **31** (57.2 mg, 46%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.67 Hz, 2H), 1.75 - 1.93 (m, 5H), 2.17 (t, *J* = 11.28 Hz, 2H), 2.94 (d, *J* = 11.42 Hz, 2H), 3.62 (s, 2H), 4.19 - 4.35 (m, 1H), 6.84 (dd, *J* = 5.71, 2.49 Hz, 1H), 7.07 (d, *J* = 2.64 Hz, 1H), 7.17 (m, 1H), 7.31 - 7.41 (m, 2H), 7.48 - 7.55 (m, 1H), 7.61 (d, *J* = 1.17 Hz, 1H), 8.41 (d, *J* = 5.56 Hz, 1H). ¹³C

NMR (75 MHz, DMSO- d_6) δ : 12.01, 29.98 (2C), 52.17, 52.45 (2C), 62.88, 108.91, 110.84 (2C), 119.17, 120.62, 125.37, 131.83, 134.22, 137.61, 150.79, 150.91, 154.83, 161.39, 163.65, 163.96. HRMS (ESI): calculated for $[C_{22}H_{23}ClN_4O_3 + H]^+$, 427.1531; found 427.1547.

1-(1-((4-(3,5-Dichlorophenoxy)pyridin-2-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (32): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (85.6 mg, 0.260 mmol), 4-(3,5-dichlorophenoxy)picolinaldehyde **48** (69.7 mg, 0.260 mmol), sodium triacetoxyborohydride (110 mg, 0.520 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - methanol eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **32** (34.2 mg, 29%). ¹H NMR (300 MHz, DMSO- d_6) δ : 1.60 - 1.72 (m, 2H), 1.78 (d, $J = 0.59$ Hz, 3H), 1.81 - 1.93 (m, 2H), 2.19 (t, $J = 10.84$ Hz, 2H), 2.96 (d, $J = 11.72$ Hz, 2H), 3.65 (s, 2H), 4.21 - 4.37 (m, 1H), 6.92 (dd, $J = 5.71, 2.49$ Hz, 1H), 7.12 (d, $J = 2.64$ Hz, 1H), 7.37 (d, $J = 2.05$ Hz, 2H), 7.55 (t, $J = 1.90$ Hz, 1H), 7.61 (d, $J = 0.88$ Hz, 4H), 8.44 (d, $J = 5.56$ Hz, 1H), 11.21 (s, 4H). ¹³C NMR (75 MHz, DMSO- d_6) δ : 12.03, 29.93 (2C), 52.08, 52.40 (2C), 62.71, 108.93, 111.13, 111.16, 119.60 (2C), 125.14, 135.17 (2C), 137.60, 150.80, 151.06, 155.47, 161.44, 163.47, 163.65. HRMS (ESI): calculated for $[C_{22}H_{22}Cl_2N_4O_3 + H]^+$, 461.1142; found 461.1141.

1-(1-((5-(3-Chlorophenoxy)pyridin-3-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (33): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (82.3 mg, 0.25 mmol), 5-(3-chlorophenoxy)nicotinaldehyde **53** (116 mg, 0.500 mmol), sodium triacetoxyborohydride (106 mg, 0.500 mmol) in dry 1,2-dichloroethane (8 mL) using ethyl acetate - methanol eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **33** (52.0 mg, 49%). ¹H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J = 9.67$ Hz, 2H), 1.74 - 1.93 (m, 5H), 2.10 (t, $J = 10.98$ Hz, 2H), 2.91 (d, $J = 11.13$ Hz, 2H), 3.58 (s, 2H), 4.19 - 4.35 (m, 1H), 7.04 (ddd, $J = 8.27, 2.42, 1.03$ Hz, 1H), 7.18 (t, $J = 2.20$ Hz,

1H), 7.22 - 7.29 (m, 1H), 7.41 - 7.49 (m, 2H), 7.63 (d, $J = 0.88$ Hz, 1H), 8.32 (d, $J = 2.34$ Hz, 1H), 8.37 (s, 1H), 11.20 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 12.00, 29.92 (2C), 52.17 (3C), 58.04, 108.91, 116.99, 118.45, 123.90, 126.36, 131.66, 134.13, 135.69, 137.64, 139.95, 145.58, 150.79, 152.33, 157.33, 163.65. HRMS (ESI): calculated for $[\text{C}_{22}\text{H}_{23}\text{ClN}_4\text{O}_3 + \text{H}]^+$, 427.1531; found 427.1545.

5-Methyl-1-(1-((5-(3-(trifluoromethoxy)phenoxy)pyridin-3-yl)methyl)piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (34): According to a literature procedure,³⁸ methyl 5-(3-(trifluoromethoxy)phenoxy)nicotinate **54** (165 mg, 0.528 mmol) was reduced by LiAlH_4 and oxidized by MnO_2 sequentially to offer the crude intermediate 5-(3-(trifluoromethoxy)phenoxy)nicotinaldehyde **55**, which was used for next step directly. Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (85.6 mg, 0.260 mmol), the obtained crude intermediate, sodium triacetoxyborohydride (110 mg, 0.520 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - methanol eluent system to obtain the intermediate which was dissolved with 80% TFA/ H_2O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **34** (34.3 mg, 28%). ^1H NMR (300 MHz, DMSO- d_6) δ : 1.65 (d, $J = 9.67$ Hz, 2H), 1.75 - 1.91 (m, 5H), 2.10 (t, $J = 10.98$ Hz, 2H), 2.91 (d, $J = 11.42$ Hz, 2H), 3.58 (s, 2H), 4.18 - 4.34 (m, 1H), 7.06 - 7.12 (m, 2H), 7.19 (dt, $J = 8.20, 1.03$ Hz, 1H), 7.44 - 7.48 (m, 1H), 7.51 - 7.58 (m, 1H), 7.62 (d, $J = 1.17$ Hz, 1H), 8.33 (d, $J = 2.64$ Hz, 1H), 8.39 (d, $J = 1.17$ Hz, 1H) 11.20 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6) δ : 11.98, 29.92 (2C), 52.17 (3C), 58.04, 108.91, 111.31, 116.04, 116.99, 121.66 (t, $J_{CF} = 225.00$ Hz), 126.58, 131.74, 135.73, 137.60, 140.07, 145.79, 149.26, 149.29, 150.79, 152.08, 157.61, 163.64, several signals cannot be found. ^{19}F NMR (282 MHz, CD_3OD) δ : -56.87. HRMS (ESI): calculated for $[\text{C}_{23}\text{H}_{23}\text{F}_3\text{N}_4\text{O}_4 + \text{H}]^+$, 477.1744; found 477.1745.

1-(1-((5-(3,5-Dichlorophenoxy)pyridin-3-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (35): According to a literature procedure,³⁹ thionyl chloride (0.99 mL, 1.4 mmol) was added dropwise to a solution of 5-(3,5-dichlorophenoxy)nicotinic acid **58** (194 mg, 0.684 mmol) in methanol (10 mL) to offer the crude nicotinate intermediate. which was first reduced by LiAlH_4 , followed

by oxidation with Dess-Martin reagent according to a literature procedure³⁸ to give nicotinaldehyde intermediate **59**. Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (71.1 mg, 0.216 mmol), 5-(3,5-dichlorophenoxy)nicotinaldehyde **59**, sodium triacetoxyborohydride (183 mg, 0.862 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - methanol eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **35** (34.5 mg, 35%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.65 (d, *J* = 9.37 Hz, 2H), 1.76 - 1.92 (m, 5H), 2.10 (t, *J* = 10.69 Hz, 2H), 2.91 (d, *J* = 11.42 Hz, 2H), 3.59 (s, 2H), 4.21 - 4.33 (m, 1H), 7.17 (d, *J* = 1.76 Hz, 2H), 7.43 (t, *J* = 1.90 Hz, 1H), 7.48 - 7.52 (m, 1H), 7.63 (d, *J* = 0.88 Hz, 1H), 8.36 (d, *J* = 2.64 Hz, 1H), 8.41 (d, *J* = 1.46 Hz, 1H), 11.19 (br. s., 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.00, 29.95 (2C), 52.16 (3C), 57.98, 108.91, 117.29 (2C), 123.61, 126.80, 135.08, 135.84, 137.63, 140.16, 146.11, 150.79, 151.78, 158.01, 163.65. HRMS (ESI): calculated for [C₂₂H₂₂Cl₂N₄O₃ + H]⁺, 461.1142; found 461.1143.

1-(1-((2-(3-Chlorophenoxy)pyridin-4-yl)methyl)piperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (36): Following the general procedure for the synthesis of final compounds: 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione (96.5 mg, 0.290 mmol), 2-(3-chlorophenoxy)isonicotinaldehyde **44** (83.6 mg, 0.350 mmol), sodium triacetoxyborohydride (93.2 mg, 0.440 mmol) in dry 1,2-dichloroethane (5 mL) using ethyl acetate - hexane eluent system to obtain the intermediate which was dissolved with 80% TFA/H₂O (30 mL) and L-cysteine hydrochloride (1.3 g, 8.1 mmol) was added to the reaction mixture to yield compound **36** (59.0 mg, 48%). ¹H NMR (300 MHz, DMSO-d₆) δ: 1.67 (d, *J* = 9.37 Hz, 2H), 1.75 - 1.98 (m, 5H), 2.14 (t, *J* = 10.98 Hz, 2H), 2.93 (d, *J* = 11.72 Hz, 2H), 3.58 (s, 2H), 4.21 - 4.36 (m, 1H), 7.05 (s, 1H), 7.09 - 7.16 (m, 2H), 7.24 - 7.32 (m, 2H), 7.39 - 7.48 (m, 1H), 7.67 (d, *J* = 1.17 Hz, 1H), 8.10 (d, *J* = 4.69 Hz, 1H), 11.20 (s, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 12.00, 29.99 (2C), 52.17, 52.42 (2C), 59.96, 108.94, 110.91, 119.51, 120.01, 121.37, 124.45,

131.00, 133.44, 137.66, 147.14, 150.82, 152.69, 154.79, 162.86, 163.67. HRMS (ESI): calculated for $[C_{22}H_{23}ClN_4O_3 + H]^+$, 427.1531; found 427.1539.

2-Bromo-6-(1,3-dioxan-2-yl)pyridine (38): According to a literature procedure,⁴⁰ **38** was obtained as white solid. ¹H NMR (300 MHz, CDCl₃) δ : 1.46 (dtt, $J = 13.55, 2.53, 2.53, 1.39, 1.39$ Hz, 1H), 2.15 - 2.32 (m, 1H), 3.96 - 4.06 (m, 2H), 4.24 - 4.32 (m, 2H), 5.53 (s, 1H), 7.43 - 7.50 (m, 1H), 7.56 - 7.63 (m, 2H). HRMS (ESI): calculated for $[C_9H_{10}BrNO_2 + H]^+$, 243.9968; found, 243.9960.

4.1.3. General procedure for Ullmann coupling:

According to a modified literature procedure,¹⁶ a suspension of the protected aromatic aldehyde (1 eq), substituted aromatic halide or substituted phenol (3 eq), Cs₂CO₃ (3 eq), and *N,N*-dimethylglycine.hydrochloride (0.3 eq) and CuI (0.1 eq) in dry 1,4-dioxane (~ 0.3 M) was heated at 90 °C under argon or under air (with a drying tube) for 24 h. After cooling to room temperature, CH₂Cl₂ (3 times the suspension volume) was added to the reaction mixture, followed by filtration through Celite®. Next, work-up was effected by employing either one of the following methods: Method 1: the filtrate was evaporated and the obtained residue was dissolved with 5 M aq. NaOH (the suspension volume) and extracted with CH₂Cl₂ (two times the suspension volume) for three times. The combined organic layers were washed with 5 N aq. NaOH (two times the suspension volume) for two times. TLC was used to check the presence of product in the water layer. If the combined water layers contain product, they need to be re-extracted with CH₂Cl₂ (two times the suspension volume) for three times. Next, all the organic layers are combined, washed with water (3 times the suspension volume) and brine (3 times the suspension volume) sequentially. After drying over Na₂SO₄ and filtration, the concentrated residue was purified with column chromatography (100% hexane – 10% ethyl acetate/hexane in linear gradient elution or 100% toluene – 10% ethyl acetate/toluene in linear gradient elution). Method 2: the filtrate was evaporated and the residue was dried with oil pump high vacuum for 0.5 h, the residue was purified with column chromatography (100% hexane/ethyl acetate – 90% hexane/ethyl acetate in linear gradient elution or 100% toluene/ethyl

acetate – 90% toluene/ethyl acetate in linear gradient elution) to offer the desired intermediate, which was used directly for the acetal hydrolysis step.

4.1.4. General procedure for acetal hydrolysis:

The obtained Ullmann coupling intermediate was dissolved with 2 M aq. HCl/ THF (v/v = 1/1, 3/4 or 4/3, ~ 0.15 M). The reaction mixture was stirred at room temperature or at 50 – 60 °C for 2 – 7 h. TLC was used to monitor the reaction progress. There are two methods for the work-up procedure. Method 1: the reaction mixture was diluted with ethyl acetate (1.5 times the solvent volume) and brine (0.5 times the solvent volume). The organic layer was separated and washed with sat. aq. NaHCO₃ (0.5 times the solvent volume) and brine (0.5 times the solvent volume) sequentially. After drying over Na₂SO₄ and filtration, the concentrated residue was purified with column chromatography (100% hexane – 10% ethyl acetate/hexane in linear gradient elution or 100% toluene – 10% ethyl acetate/toluene in linear gradient elution). Method 2: the reaction mixture was neutralized with sat. aq. NaHCO₃ solution (0.5 times the solvent volume), followed by extraction with ethyl acetate (the solvent volume) for three times. The combined organic layers were washed with water (the solvent volume) and brine (the solvent volume) sequentially. After drying over Na₂SO₄ and filtration, the concentrated residue was purified with column chromatography (100% hexane – 10% ethyl acetate/hexane in linear gradient elution or 100% toluene – 10% ethyl acetate/toluene in linear gradient elution).

6-Phenoxypicolinaldehyde (39): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 2), the suspension of 2-bromo-4-(1,3-dioxan-2-yl)pyridine **38** (0.49 g, 2.0 mmol), phenol (0.56 g, 6.0 mmol), Cs₂CO₃ (2.0 g, 6.0 mmol), *N,N*-dimethylglycine hydrochloride (84 mg, 0.60 mmol) and CuI (38.1 mg, 0.2 mmol) in dry 1,4-dioxane (8 mL) under air with a drying tube yielded the intermediate, which was dissolved with 2 M aq. HCl/ THF (20 mL/15 mL) at room temperature. The reaction mixture was heated at 50 °C to offer compound **39** as light yellow solid (129 mg, 32%). ¹H NMR (300 MHz, CDCl₃) δ: 7.12 (dd, *J* = 8.20, 0.88 Hz, 1H), 7.17 - 7.23 (m, 2H), 7.24

- 7.29 (m, 1H), 7.40 - 7.47 (m, 2H), 7.69 (dd, $J = 7.32, 0.88$ Hz, 1H), 7.85 (ddd, $J = 8.20, 7.32, 0.88$ Hz, 1H), 9.85 (d, $J = 0.59$ Hz, 1H). HRMS (ESI): calculated for $[C_{12}H_9NO_2 + H]^+$, 200.0706; found, 200.0714.

6-(3-Chlorophenoxy)picolinaldehyde (40): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 2), the suspension of 2-bromo-4-(1,3-dioxan-2-yl)pyridine **38** (0.49 g, 2.0 mmol), 3-chlorophenol (0.77 g, 6.0 mmol), Cs_2CO_3 (3.0 g, 6.0 mmol), *N,N*-dimethylglycine hydrochloride (84 mg, 0.60 mmol) and CuI (38 mg, 0.20 mmol) in dry 1,4-dioxane (8 mL) under air with a drying tube yielded the intermediate, which was dissolved with 2 M aq. HCl / THF (20 mL/15 mL) at room temperature. The reaction mixture was heated at 50 °C to offer compound **40** as light yellow gel (280 mg, 54%). 1H NMR (300 MHz, $CDCl_3$) δ : 7.08 - 7.12 (m, 1H), 7.16 (dd, $J = 7.91, 0.88$ Hz, 1H), 7.21 - 7.25 (m, 2H), 7.32 - 7.39 (m, 1H), 7.72 (dd, $J = 7.32, 0.88$ Hz, 1H), 7.86 - 7.92 (m, 1H), 9.83 (d, $J = 0.59$ Hz, 1H). HRMS (ESI): calculated for $[C_{12}H_9ClNO_2 + H]^+$, 234.0316; found, 234.0325.

2-Bromo-4-(1,3-dioxan-2-yl)pyridine (42): According to a literature procedure,⁴⁰ compound **42** was obtained as colorless oil. 1H NMR (300 MHz, $CDCl_3$) δ : 1.43 - 1.53 (m, 1H), 2.11 - 2.29 (m, 1H), 3.92 - 4.03 (m, 2H), 4.23 - 4.32 (m, 2H), 5.45 (s, 1H), 7.32 - 7.37 (m, 1H), 7.61 (d, $J = 0.59$ Hz, 1H), 8.36 (dd, $J = 4.98, 0.59$ Hz, 1H). HRMS (ESI): calculated for $[C_9H_{10}BrNO_2 + H]^+$, 243.9968; found, 243.9973.

2-Phenoxyisonicotinaldehyde (43): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 2), the suspension of 2-bromo-4-(1,3-dioxan-2-yl)pyridine **42** (0.38 g, 1.6 mmol), phenol (0.44 g, 4.7 mmol), Cs_2CO_3 (1.5 g, 4.7 mmol), *N,N*-dimethylglycine hydrochloride (65 mg, 0.47 mmol) and CuI (30 mg, 0.16 mmol) in dry 1,4-dioxane (4 mL) under air with a drying tube yielded the intermediate, which was dissolved with 2 M aq. HCl/ THF (10 mL/10 mL) at room temperature. The reaction mixture was heated at 50 °C to offer compound **43** as colorless oil (80 mg, 26%). 1H NMR (300 MHz, $CDCl_3$) δ : 7.13 - 7.19 (m, 2H), 7.22 - 7.29 (m, 1H), 7.30 (dd, $J = 1.32, 0.73$ Hz, 1H), 7.40 - 7.47 (m, 3H), 8.41 (d, $J = 5.27$ Hz, 1H), 10.05 (s, 1H). HRMS (ESI): calculated for $[C_{12}H_9NO_2 + H]^+$, 200.0706; found, 200.0712.

4-Phenoxypicolinaldehyde (46): Following the general procedure of Ullmann coupling (work-up method 2), 4-bromo-2-methylpyridine **45** (0.86 g, 5.0 mmol), phenol (1.4 g, 15 mmol), Cs₂CO₃ (4.9 g, 15 mmol), *N,N*-dimethylglycine hydrochloride (210 mg, 1.5 mmol) and CuI (95 mg, 0.50 mmol) in dry 1,4-dioxane (10 mL) under air with a drying tube yielded the intermediate as colorless oil (380 mg, 41%), the obtained intermediate (148 mg, 0.800 mmol) and SeO₂ (178 mg, 1.60 mmol) was dissolved in 1,4-dioxane (6 mL) and the suspension was heated at 80 °C for overnight. After cooling to room temperature, the mixture was filtered through Celite® and the filtrate was evaporated and purified with column chromatography (100 % hexane - 20% ethyl acetate/hexane in linear gradient elution) to offer compound **46** as yellow gel (20 mg, 17 %). ¹H NMR (300 MHz, CDCl₃) δ: 7.06 - 7.13 (m, 3H), 7.27 - 7.33 (m, 1H), 7.42 - 7.50 (m, 3H), 8.63 (d, *J* = 5.56 Hz, 1H), 10.03 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 109.42, 115.97, 120.84 (2C), 126.03, 130.47 (2C), 151.70, 153.50, 154.86, 165.95, 192.93. HRMS (ESI): calculated for [C₁₂H₉NO₂ + H]⁺, 200.0706; found, 200.0703.

4-(3-Chlorophenoxy)picolinaldehyde (47): Following the general procedure of Ullmann coupling (work-up method 2), 4-bromo-2-methylpyridine **45** (0.86 g, 5.0 mmol), 3-chlorophenol (1.9 g, 15 mmol), Cs₂CO₃ (4.9 g, 15 mmol), *N,N*-dimethylglycine hydrochloride (209 mg, 1.50 mmol) and CuI (95 mg, 0.50 mmol) in dry 1,4-dioxane (10 mL) under air with a drying tube yielded the intermediate as colorless oil (641 mg, 58%), the obtained intermediate (176 mg, 0.800 mmol) and SeO₂ (177 mg, 1.60 mmol) were dissolved in 1,4-dioxane (6 mL) and the suspension was heated at 80 °C for overnight. After cooling to room temperature, the mixture was filtered through Celite® and the filtrate was evaporated and purified with column chromatography (100 % hexane - 20% ethyl acetate/hexane in linear gradient elution) to offer compound **47** as colorless gel (30.0 mg, 16 %). ¹H NMR (300 MHz, CDCl₃) δ: 6.98 - 7.04 (m, 1H), 7.09 (dd, *J* = 5.56, 2.64 Hz, 1H), 7.13 (t, *J* = 2.05 Hz, 1H), 7.27 - 7.31 (m, 1H), 7.36 - 7.43 (m, 1H), 7.43 - 7.47 (m, 1H), 8.66 (dd, *J* = 5.56, 0.59 Hz, 1H), 10.04 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 109.54, 116.11, 119.01, 121.39, 126.30, 131.23, 135.78, 151.87, 154.21, 155.00, 165.35, 192.74. HRMS (ESI): calculated for [C₁₂H₈ClNO₂ + H]⁺, 234.0316; found, 234.0312.

4-(3,5-Dichlorophenoxy)picolinaldehyde (48): According to a literature procedure,¹⁷ a suspension of 4-bromo-2-methylpyridine **45** (0.52 g, 3.0 mmol), 3,5-dichlorophenol (0.98 g, 6.0 mmol), K₃PO₄ (1.3 g, 6.0 mmol), picolinic acid (74 mg, 0.60 mmol) and CuI (57 mg, 0.30 mmol) in dry DMF (5 mL) yielded the intermediate 4-(3,5-dichlorophenoxy)-2-methylpyridine as white solid (0.31 g, 41%). ¹H NMR (300 MHz, CDCl₃) δ: 2.54 (s, 3H), 6.68 - 6.74 (m, 2H), 6.99 (d, *J* = 1.76 Hz, 2H), 7.23 (t, *J* = 1.76 Hz, 1H), 8.41 (d, *J* = 5.57 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 24.49, 110.08, 111.99, 119.15 (2C), 125.28, 135.92, 150.90, 155.55, 160.97, 163.66. HRMS (ESI): calculated for [C₁₂H₉Cl₂NO + H]⁺, 254.0134; found, 254.0125. According to a modified literature procedure,⁴¹ the suspension of 4-(3,5-dichlorophenoxy)-2-methylpyridine (160 mg, 0.63 mmol) and SeO₂ (210 mg, 1.9 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 24 h. After cooling to room temperature, the reaction mixture was filtered through Celite®. The filtrate was evaporated and purified with column chromatography (100% hexane – 10 % ethyl acetate/hexane) to offer compound **48** as white solid (34.7 mg, 21%). ¹H NMR (300 MHz, CDCl₃) δ: 7.03 (d, *J* = 1.76 Hz, 2H), 7.12 (dd, *J* = 5.56, 2.64 Hz, 1H), 7.30 (t, *J* = 1.90 Hz, 1H), 7.47 (d, *J* = 2.64 Hz, 1H), 8.70 (d, *J* = 5.56 Hz, 1H), 10.05 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 109.79, 116.30, 119.63 (2C), 126.36, 136.39, 152.05, 154.66, 155.14, 164.72, 192.55. HRMS (ESI): calculated for [C₁₂H₇Cl₂NO₂ + H]⁺, 267.9927; found, 267.9925.

Methyl 5-phoxynicotinate (50): According to a literature procedure,⁴² to the reaction mixture of methyl 5-hydroxynicotinate **49** (0.77 g, 5.0 mmol), phenylboronic acid (2.1 g, 18 mmol), Cu(OAc)₂ (1.8 g, 10 mol) and 4Å molecular sieves (2.5 g) in CH₂Cl₂ (40 mL) was added Et₃N (5 mL). The reaction mixture was stirred at room temperature under air with a drying tube for 24 h. The crude product was purified by silica chromatography (10% ethyl acetate/hexane – 50% ethyl acetate/hexane in linear gradient) to offer compound **50** as colorless gel (163 mg, 20%). ¹H NMR (300 MHz, CDCl₃) δ: 3.93 (s, 3H), 7.02 - 7.07 (m, 2H), 7.21 (tt, *J* = 7.36, 1.14 Hz, 1H), 7.37 - 7.44 (m, 2H), 7.84 (dd, *J* = 2.93, 1.76 Hz, 1H), 8.57 (d, *J* = 2.93 Hz, 1H), 8.95 (d, *J* = 1.76 Hz, 1H).

5-Phoxynicotinaldehyde (51): According to a literature procedure,³⁸ methyl 5-phoxynicotinate **50** (183 g, 0.800 mmol) was used for reduction by LiAlH₄ and oxidation by MnO₂ sequentially to offer compound **51** as light yellow gel (64 mg, 40%). ¹H NMR (300 MHz, CDCl₃) δ: 7.04 - 7.10 (m, 2H), 7.21 - 7.28 (m, 1H), 7.39 - 7.46 (m, 2H), 7.65 (dd, *J* = 2.93, 1.76 Hz, 1H), 8.66 (d, *J* = 2.64 Hz, 1H), 8.79 (d, *J* = 1.76 Hz, 1H), 10.08 (s, 1H). HRMS (ESI): calculated for [C₁₂H₉NO₂ + H]⁺, 200.0706; found, 200.0709.

Methyl 5-(3-chlorophenoxy)nicotinate (52): According to a literature procedure,⁴² to the suspension of methyl 5-hydroxynicotinate **49** (0.38 g, 2.5 mmol), 3-chlorophenylboronic acid (1.17 g, 7.50 mmol), Cu(OAc)₂ (0.91 g, 5.0 mol) and 4Å molecular sieves (1.3 g) in CH₂Cl₂ (20 mL) was added Et₃N (2.5 mL). The reaction mixture was stirred at room temperature under air with a drying tube for 24 h to offer compound **52** as light yellow gel (112 mg, 17%). ¹H NMR (300 MHz, CDCl₃) δ: 3.95 (s, 3H), 6.93 (ddd, *J* = 8.20, 2.34, 0.88 Hz, 1H), 7.04 (t, *J* = 2.20 Hz, 1H), 7.16 - 7.20 (m, 1H), 7.27 - 7.35 (m, 1H), 7.86 (dd, *J* = 2.64, 1.76 Hz, 1H), 8.58 (d, *J* = 2.64 Hz, 1H), 9.00 (d, *J* = 1.46 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 52.63, 117.16, 119.52, 124.81, 126.07, 127.00, 130.97, 135.57, 145.29, 145.73, 153.17, 156.63, 165.12. HRMS (ESI): calculated for [C₁₃H₁₀ClNO₃ + H]⁺, 264.0422; found, 264.0431.

5-(3-Chlorophenoxy)nicotinaldehyde (53): According to a literature procedure,³⁸ methyl 5-(3-chlorophenoxy)nicotinate **52** (171 mg, 0.650 mmol) was reduced by LiAlH₄ and oxidized by MnO₂ sequentially to offer compound **53** as colorless gel (20.0 mg, 13%). ¹H NMR (300 MHz, CDCl₃) δ: 6.96 (ddd, *J* = 8.13, 2.42, 0.88 Hz, 1H), 7.07 (t, *J* = 2.20 Hz, 1H), 7.18 - 7.25 (m, 1H), 7.35 (t, *J* = 8.20 Hz, 1H), 7.69 (dd, *J* = 2.78, 1.61 Hz, 1H), 8.66 (d, *J* = 2.64 Hz, 1H), 8.81 - 8.87 (m, 1H), 10.10 (s, 1H). HRMS (ESI): calculated for [C₁₂H₈ClNO₂ + H]⁺, 234.0316; found, 234.0327.

Methyl 5-(3-(trifluoromethoxy)phenoxy)nicotinate (54): According to a literature procedure,⁴² to a reaction mixture of methyl 5-hydroxynicotinate **49** (0.36 g, 2.4 mmol), (3-(trifluoromethoxy)phenyl)boronic acid (1.45 g, 7.04 mmol), Cu(OAc)₂ (0.85 g, 4.7 mol) and 4Å molecular sieves (1.18 g) in CH₂Cl₂ (10 mL) was added Et₃N (2.35 mL). The reaction mixture was stirred at room

temperature under air with a drying tube for 24 h to offer the compound **54** as light yellow gel (37.0 mg, 5%). ¹H NMR (300 MHz, CDCl₃) δ: 3.95 (s, 3H), 6.91 - 6.98 (m, 2H), 7.07 (dt, *J* = 8.20, 1.03 Hz, 1H), 7.37 - 7.45 (m, 1H), 7.91 (dd, *J* = 2.78, 1.61 Hz, 1H), 8.59 (d, *J* = 2.93 Hz, 1H), 9.02 (d, *J* = 1.46 Hz, 1H). HRMS (ESI): calculated for [C₁₅H₁₂F₃NO₃ + H]⁺, 312.0842; found, 312.0855.

3-(3,5-Dichlorophenoxy)-5-methylpyridine (57): According to a literature procedure,¹⁷ a suspension of 3-bromo-5-methylpyridine **56** (0.52 g, 3.0 mmol), 3,5-dichlorophenol (0.73 g, 4.5 mmol), K₃PO₄ (1.3 g, 6.0 mmol), picolinic acid (74 mg, 0.60 mmol) and CuI (57 mg, 0.30 mmol) in dry DMF (6 mL) yielded the compound **57** as white solid (0.35 g, 46%). ¹H NMR (300 MHz, CDCl₃) δ: 2.37 (s, 3H), 6.88 (d, *J* = 2.05 Hz, 2H), 7.12 (t, *J* = 1.76 Hz, 1H), 7.15 - 7.18 (m, 1H), 8.23 (br. s., 1H), 8.30 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 18.75, 117.46 (2C), 124.36, 127.83, 135.32, 136.33 (2C), 139.60, 146.86, 152.48, 158.63. HRMS (ESI): calculated for [C₁₂H₉Cl₂NO + H]⁺, 254.0134; found, 254.0129.

5-(3,5-Dichlorophenoxy)nicotinic acid (58): According to a literature procedure,⁴³ to a gently refluxing solution of **57** (0.30 g, 1.2 mmol) in pyridine (8.4 mL) and H₂O (6 mL) was added KMnO₄ (2.2 g, 14 mmol) in several portions to offer the product **58** (0.19 g, 56%) as white solid. ¹H NMR (300 MHz, DMSO-d₆) δ: 7.26 - 7.30 (m, 2H), 7.47 (s, 1H), 7.85 (dd, *J* = 2.93, 1.76 Hz, 1H), 8.70 (d, *J* = 2.64 Hz, 1H), 8.92 (d, *J* = 1.46 Hz, 1H), 13.65 (br. s., 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ: 118.01 (2C), 124.24, 126.39, 127.95, 135.14 (2C), 145.27, 145.93, 152.16, 157.38, 165.56.

3-(1,3-Dioxan-2-yl)phenol (61): To the solution of 3-hydroxybenzaldehyde **60** (25 g, 0.20 mol) in pyridine (100 mL) was added acetic anhydride (25 mL, 0.27 mmol) under argon in an ice bath. The reaction mixture was stirred at room temperature for 1 h, followed by dilution with cold brine (200 mL) in an ice bath. The solution was extracted with ethyl acetate (2 × 100 mL). The combined organic layer was washed with 1.2 M aq. HCl solution (2 × 100 mL), sat. NaHCO₃ solution (2 × 100 mL) and brine (100 mL) sequentially. After drying over Na₂SO₄, evaporation in vacuum gave the crude intermediate, which was refluxing with 1,3-propanediol (19 g, 0.24 mol) in toluene (150 mL) containing *p*-toluenesulfonic acid (0.86

g, 4.5 mmol). Water was removed with a Dean-Stark trap. After 2 h, the production of water ceased and the mixture was allowed to cool to ambient temperature. A solution of 10% NaOH in water was added and the mixture was stirred vigorously for 2 h. the pH was adjusted to 8 with concentrated HCl solution. The mixture was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over Na₂SO₄ and evaporated. The residue was purified with column chromatography (3% ethyl acetate/toluene – 8% ethyl acetate/toluene in linear gradient elution) to offer compound **61** as white solid (15.8 g, 43%). ¹H NMR (300 MHz, CDCl₃) δ: 1.45 (m, 1H), 2.23 (m, 1H), 3.93 - 4.04 (m, 2H), 4.23 - 4.31 (m, 2H), 4.86 (s, 1H), 5.46 (s, 1H), 6.77 - 6.81 (m, 1H), 6.97 (dd, *J* = 2.64, 1.46 Hz, 1H), 7.01 - 7.06 (m, 1H), 7.19 - 7.25 (m, 1H). HRMS (ESI): calculated for [C₁₀H₁₂O₃ + H]⁺, 181.0859; found 181.0852.

3-(Pyridin-2-yloxy)benzaldehyde (62): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 2), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.72 g, 4.0 mmol), 2-bromopyridine (1.9 g, 12 mmol), Cs₂CO₃ (3.9 g, 12 mmol), *N,N*-dimethylglycine hydrochloride (170 mg, 1.2 mmol) and CuI (76.2 mg, 0.400 mmol) in dry 1,4-dioxane (15 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/ THF (15 mL/15 mL) to offer compound **62** as a colorless oil (0.67 g, 90%). ¹H NMR (300 MHz, CDCl₃) δ: 6.99 (dt, *J* = 8.20, 0.88 Hz, 1H), 7.05 (ddd, *J* = 7.32, 4.98, 0.88 Hz, 1H), 7.40 - 7.46 (m, 1H), 7.57 (t, *J* = 7.76 Hz, 1H), 7.66 (dd, *J* = 2.05, 1.46 Hz, 1H), 7.70 - 7.77 (m, 2H), 8.19 (ddd, *J* = 4.98, 2.05, 0.88 Hz, 1H), 10.01 (s, 1H). HRMS (ESI): calculated for [C₁₂H₁₉NO₂ + H]⁺, 200.0706; found 200.0699.

3-(Pyridin-3-yloxy)benzaldehyde (63): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 2), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (1.08 g, 6 mmol), 3-bromopyridine (2.8 g, 18 mmol), Cs₂CO₃ (5.9 g, 18 mmol), *N,N*-dimethylglycine hydrochloride (0.25 g, 1.8 mmol) and CuI (114 mg, 0.600 mmol) in dry 1,4-dioxane (15 mL) under argon yielded the intermediate, which was dissolved with 2 N HCl/ THF (5 mL/5 mL) to offer compound **63** as colorless oil (139 mg, 12%). ¹H NMR (300 MHz, CDCl₃) δ: 7.29 - 7.36 (m, 3H), 7.48 - 7.50 (m, 1H), 7.55

(t, $J = 7.76$ Hz, 1H), 7.67 (dt, $J = 7.40, 1.28$ Hz, 1H), 8.43 - 8.46 (m, 2H), 9.98 (s, 1H). HRMS (ESI): calculated for $[C_{12}H_{19}NO_2 + H]^+$, 200.0706; found 200.0711.

3-(Pyridin-4-yloxy)benzaldehyde (64): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (1.1 g, 6 mmol), 4-bromopyridine hydrochloride (3.5 g, 18 mmol), CS_2CO_3 (8.8 g, 27 mmol), *N,N*-dimethylglycine hydrochloride (0.25 g, 1.8 mmol) and CuI (114 mg, 0.600 mmol) in dry 1,4-dioxane (15 mL) under argon yielded the intermediate, which was dissolved with 2 N HCl/ THF (12 mL/12 mL) to offer compound **64** as a colorless oil (0.50 g, 42%). 1H NMR (300 MHz, $CDCl_3$) δ : 6.85 - 6.89 (m, 2H), 7.38 (ddd, $J = 7.98, 2.56, 1.17$ Hz, 1H), 7.58 - 7.65 (m, 2H), 7.75 - 7.79 (m, 1H), 8.50 - 8.54 (m, 2H), 10.02 (s, 1H). HRMS (ESI): calculated for $[C_{12}H_{19}NO_2 + H]^+$, 200.0706; found 200.0701.

3-(Cyclopentyloxy)benzaldehyde (66): According to a literature procedure,⁴⁴ the compound **66** was obtained as colorless oil. 1H NMR (300 MHz, $CDCl_3$) δ : 1.62 - 2.02 (m, 8H), 4.83 (tt, $J = 5.57, 2.78$ Hz, 1H), 7.10 - 7.17 (m, 1H), 7.36 (dt, $J = 2.64, 0.88$ Hz, 1H), 7.38 - 7.46 (m, 2H), 9.96 (s, 1H). HRMS (ESI): calculated for $[C_{12}H_{14}O_2 + H]^+$, 191.1067; found 191.1062.

3-(Cyclohexyloxy)benzaldehyde (68): According to a literature procedure,⁴⁴ the compound **68** was obtained as colorless oil. 1H NMR (300 MHz, $CDCl_3$) δ : 1.31 - 1.64 (m, 6H), 1.75 - 1.88 (m, 2H), 1.92 - 2.06 (m, 2H), 4.28 - 4.39 (m, 1H), 7.13 - 7.20 (m, 1H), 7.36 - 7.46 (m, 3H), 9.96 (s, 1H). HRMS (ESI): calculated for $[C_{13}H_{16}O_2 + H]^+$, 205.1223; found 205.1215.

2-(3-Bromophenyl)-1,3-dioxane (70): According to a literature procedure,⁴⁰ **70** was obtained as colorless gel. 1H NMR (300 MHz, $CDCl_3$) δ : 1.41 (m, 1H), 2.08 - 2.27 (m, 1H), 3.88 - 4.00 (m, 2H), 4.17 - 4.30 (m, 2H), 5.44 (s, 1H), 7.17 - 7.24 (m, 1H), 7.36 - 7.47 (m, 2H), 7.65 (t, $J = 1.76$ Hz, 1H). HRMS (ESI): calculated for $[C_{10}H_{11}BrO_2 + H]^+$, 243.0015; found 243.0012.

2-(3-Iodophenyl)-1,3-dioxane (72): According to a literature procedure,⁴⁰ **72** was obtained as colorless oil. ¹H NMR (300 MHz, CDCl₃) δ: 1.43 (m, 1H), 2.20 (m, 1H), 3.90 - 4.02 (m, 2H), 4.20 - 4.30 (m, 2H), 5.43 (s, 1H), 7.05 - 7.12 (m, 1H), 7.40 - 7.46 (m, 1H), 7.66 (dq, *J* = 7.91, 0.98 Hz, 1H), 7.85 (t, *J* = 1.76 Hz, 1H). HRMS (ESI): calculated for [C₁₀H₁₁IO₂ + H]⁺, 290.9876; found 290.9867.

3-(4-Chlorophenoxy)benzaldehyde (73): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (1.5 g, 6.0 mmol), 4-chlorophenol (2.3 g, 18 mmol), Cs₂CO₃ (5.9 g, 18 mmol), *N,N*-dimethylglycine hydrochloride (0.25 g, 1.8 mmol) and CuI (114 mg, 0.600 mmol) in dry 1,4-dioxane (10 mL) under argon yielded the intermediate, which was dissolved with 2 M HCl/THF (20 mL/20 mL) to offer compound **73** as a colorless oil (0.47 g, 33%). ¹H NMR (300 MHz, CDCl₃) δ: 6.94 - 7.01 (m, 2H), 7.25 - 7.30 (m, 1H), 7.31 - 7.37 (m, 2H), 7.45 (dd, *J* = 2.64, 1.46 Hz, 1H), 7.52 (t, *J* = 7.91 Hz, 1H), 7.60 - 7.65 (m, 1H), 9.97 (s, 1H). HRMS (ESI): calculated for [C₁₃H₉ClO₂ + MeCN + H]⁺, 274.0629; found 247.0611.

3-(4-Methoxyphenoxy)benzaldehyde (74): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (0.24 g, 1.0 mmol), 4-methoxyphenol (0.37 g, 3.0 mmol), Cs₂CO₃ (0.98 g, 3.0 mmol), *N,N*-dimethylglycine hydrochloride (42 mg, 0.30 mmol) and CuI (20 mg, 0.10 mmol) in dry 1,4-dioxane (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq HCl/THF (5 mL/5 mL) to offer compound **74** as a colorless oil (88 mg, 39%). ¹H NMR (300 MHz, CDCl₃) δ: 3.84 (s, 3H), 6.90 - 6.96 (m, 2H), 6.99 - 7.05 (m, 2H), 7.23 - 7.28 (m, 1H), 7.39 - 7.41 (m, 1H), 7.45 - 7.51 (m, 1H), 7.54 - 7.58 (m, 1H), 9.95 (s, 1H). HRMS (ESI): calculated for [C₁₄H₁₂O₃ + H]⁺, 229.0859; found 229.0849.

3-(*p*-Tolyloxy)benzaldehyde (75): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (1.6 g, 6.5 mmol), *p*-cresol (2.1 g, 20 mmol), Cs₂CO₃ (6.4 g, 20 mmol), *N,N*-dimethylglycine hydrochloride (0.27 g, 2.0 mmol) and CuI (124 mg, 0.650 mmol) in dry 1,4-dioxane (15 mL) under argon yielded the

intermediate, which was dissolved with 2 M aq. HCl/THF (12 mL/12 mL) to offer compound **75** as yellow oil (0.72 g, 52%). ¹H NMR (300 MHz, CDCl₃) δ: 2.36 (s, 3H), 6.91 - 6.97 (m, 2H), 7.15 - 7.21 (m, 2H), 7.24 - 7.29 (m, 1H), 7.41 - 7.43 (m, 1H), 7.48 (t, *J* = 7.76 Hz, 1H), 7.55 - 7.59 (m, 1H), 9.95 (s, 1H). HRMS (ESI): calculated for [C₁₄H₁₂O₂ + H]⁺, 213.0910; found 213.0903.

3-(3,4-Dichlorophenoxy)benzaldehyde (76): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (1.46 g, 6 mmol), 3,4-dichlorophenol (2.93 g, 18 mmol), Cs₂CO₃ (5.86 g, 18 mmol), *N,N*-dimethylglycine hydrochloride (0.25 g, 1.8 mmol) and CuI (114.3 mg, 0.6 mmol) in dry 1,4-dioxane (15 mL) under argon yielded the intermediate, which was dissolved with 2 N HCl/ THF (8 mL/8 mL) to offer compound **76** as a white solid (220.8 mg, 14%). ¹H NMR (300 MHz, CDCl₃) δ: 6.89 (dd, *J* = 8.79, 2.93 Hz, 1H), 7.13 (d, *J* = 2.64 Hz, 1H), 7.27 - 7.32 (m, 1H), 7.43 (d, *J* = 8.79 Hz, 1H), 7.47 - 7.50 (m, 1H), 7.55 (t, *J* = 7.76 Hz, 1H), 7.67 (dt, *J* = 7.62, 1.32 Hz, 1H), 9.99 (s, 1H). HRMS (ESI): calculated for [C₁₃H₈Cl₂O₂ + H]⁺, 266.9974; found 266.9968.

3-(3-Chlorophenoxy)benzaldehyde (77): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (0.73 g, 3.0 mmol), 3-chlorophenol (1.2 g, 9.0 mmol), Cs₂CO₃ (2.9 g, 9.0 mmol), *N,N*-dimethylglycine hydrochloride (0.13 g, 0.90 mmol) and CuI (57 mg, 0.30 mmol) in dry 1,4-dioxane (10 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (5 mL/5 mL) to offer compound **77** as a colorless oil (147 mg, 21%). ¹H NMR (300 MHz, CDCl₃) δ: 6.92 (ddd, *J* = 8.20, 2.49, 1.03 Hz, 1H), 7.02 (t, *J* = 2.20 Hz, 1H), 7.12 - 7.16 (m, 1H), 7.26 - 7.32 (m, 2H), 7.47 - 7.50 (m, 1H), 7.54 (t, *J* = 7.76 Hz, 1H), 7.65 (dt, *J* = 7.62, 1.32 Hz, 1H), 9.98 (s, 1H). HRMS (ESI): calculated for [C₁₃H₉ClO₂ + H]⁺, 233.0364; found 233.0369.

3-(*m*-Tolyloxy)benzaldehyde (78): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-iodophenyl)-1,3-dioxane **72** (1.5 g,

5.0 mmol), *m*-cresol (1.6 g, 15 mmol), Cs₂CO₃ (4.9 g, 15 mmol), *N,N*-dimethylglycine hydrochloride (209 mg, 1.50 mmol) and CuI (95 mg, 0.50 mmol) in dry 1,4-dioxane (20 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (20 mL/20 mL) to offer compound **78** as a colorless oil (534 mg, 50%). ¹H NMR (300 MHz, CDCl₃) δ: 2.34 (s, 3H), 6.80 - 6.87 (m, 2H), 6.97 (dd, *J* = 7.62, 0.59 Hz, 1H), 7.21 - 7.29 (m, 2H), 7.43 - 7.51 (m, 2H), 7.56 - 7.60 (m, 1H), 9.94 (s, 1H). HRMS (ESI): calculated for [C₁₄H₁₂O₂ + H]⁺, 213.0910; found 213.0902.

3-(3-Methoxyphenoxy)benzaldehyde (79): Following the general procedure of Ullmann coupling (work-up method 1) and the acetal hydrolysis (method 1), the suspension of 2-(3-bromophenyl)-1,3-dioxane **70** (0.73 g, 3.0 mmol), 3-methoxyphenol (1.1 g, 9.0 mmol), Cs₂CO₃ (2.9 g, 9.0 mmol), *N,N*-dimethylglycine hydrochloride (0.13 g, 0.90 mmol) and CuI (57 mg, 0.30 mmol) in dry 1,4-dioxane (10 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer compound **79** as a colorless oil (255 mg, 37%). ¹H NMR (300 MHz, CDCl₃) δ: 3.79 (s, 3H), 6.58 - 6.64 (m, 2H), 6.69 - 6.74 (m, 1H), 7.23 - 7.32 (m, 2H), 7.47 - 7.53 (m, 2H), 7.59 - 7.63 (m, 1H), 9.96 (s, 1H). HRMS (ESI): calculated for [C₁₄H₁₂O₃ + H]⁺, 229.0859; found 229.0862.

3-((*tert*-Butyldimethylsilyloxy)phenol (83): According to a literature procedure,⁴⁵ to a solution of resorcinol **82** (2.75 g, 25.0 mmol) in dry DMF (20 mL) was added the mixture of imidazole (2.55 g, 37.5 mmol), *t*-butyldimethylsilyl chloride (3.77 g, 25.0 mmol). The desired product **83** was obtained as a colorless gel (2.80 g, 50%). ¹H NMR (300 MHz, CDCl₃) δ: 0.19 (s, 6H), 0.97 (s, 9H), 6.33 - 6.37 (m, 1H), 6.43 (dd, *J* = 8.20, 2.34 Hz, 2H), 7.06 (t, *J* = 8.05 Hz, 1H). HRMS (ESI): calculated for [C₁₂H₂₀O₂Si + H]⁺, 225.1305; found, 225.1308.

3-(3-Fluorophenoxy)benzaldehyde (84): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.32 g, 1.8 mmol), 1-fluoro-3-iodobenzene (1.2 g, 5.4 mmol), Cs₂CO₃ (1.8 g, 5.4 mmol), *N,N*-dimethylglycine hydrochloride (75 mg, 0.54 mmol) and CuI (34 mg, 0.10 mmol) in dry 1,4-dioxane (4 mL) under argon

yielded the intermediate, which was dissolved with 2 M aq. HCl/ THF (10 mL/10 mL) to offer compound **84** as a yellow oil (215 mg, 55%). ¹H NMR (300 MHz, CDCl₃) δ: 6.72 - 6.74 (m, 1H), 6.85 - 6.90 (m, 2H), 7.32 - 7.36 (m, 2H), 7.50 - 7.57 (m, 2H), 7.66 (d, *J* = 7.62 Hz, 1 H), 9.98 (s, 1H). HRMS (ESI): calculated for [C₁₃H₉FO₂ + H]⁺, 217.0659; found 217.0667.

3-(4-Chloro-3-(trifluoromethyl)phenoxy)benzaldehyde (85): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.50 g, 2.8 mmol), 1-chloro-4-iodo-2-(trifluoromethyl)benzene (2.8 g, 8.4 mmol), Cs₂CO₃ (2.7 g, 8.4 mmol), *N,N*-dimethylglycine hydrochloride (0.12 g, 0.84 mmol) and CuI (53 mg, 0.28 mmol) in dry 1,4-dioxane (10 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer compound **85** as a light yellow solid (0.45 g, 53%). ¹H NMR (300 MHz, CDCl₃) δ: 7.09 - 7.15 (m, 1H), 7.28 - 7.33 (m, 1H), 7.36 (d, *J* = 2.93 Hz, 1H), 7.45 - 7.52 (m, 2H), 7.57 (t, *J* = 7.76 Hz, 1H), 7.69 (dt, *J* = 7.47, 1.39 Hz, 1H), 9.99 (s, 1H). HRMS (ESI): calculated for [C₁₄H₈ClF₃O₂ + H]⁺, 301.0238; found, 301.0229.

3-(3,4-Difluorophenoxy)benzaldehyde (86): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.32 g, 1.8 mmol), 1,2-difluoro-4-iodobenzene (1.3 g, 5.4 mmol), Cs₂CO₃ (1.7 g, 5.4 mmol), *N,N*-dimethylglycine hydrochloride (75 mg, 0.54 mmol) and CuI (34 mg, 0.10 mmol) in dry 1,4-dioxane (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer compound **86** as a colorless oil (132 mg, 31%). ¹H NMR (300 MHz, CDCl₃) δ: 6.73 - 6.81 (m, 1 H) 6.88 (ddd, *J* = 10.98, 6.59, 2.93 Hz, 1H), 7.11 - 7.21 (m, 1H), 7.26 - 7.31 (m, 1H), 7.45 (dd, *J* = 2.64, 1.46 Hz, 1H), 7.53 (t, *J* = 7.91 Hz, 1H), 7.62 - 7.67 (m, 1H), 9.98 (s, 1H). HRMS (ESI): calculated for [C₁₃H₈F₂O₂ + H]⁺, 235.0565; found 235.0559.

3-(3-(Trifluoromethyl)phenoxy)benzaldehyde (87): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-

yl)phenol **61** (0.50 g, 2.8 mmol), 1-iodo-3-(trifluoromethyl)benzene (2.3 g, 8.4 mmol), Cs₂CO₃ (2.7 g, 8.4 mmol), *N,N*-dimethylglycine hydrochloride (0.12 g, 0.84 mmol) and CuI (53 mg, 0.28 mmol) in dry 1,4-dioxane (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (15 mL/15 mL) to offer compound **87** as a colorless oil (0.52 g, 67%). ¹H NMR (300 MHz, CDCl₃) δ: 7.17 - 7.22 (m, 1H), 7.26 - 7.34 (m, 2H), 7.39 - 7.52 (m, 3H), 7.55 (t, *J* = 7.76 Hz, 1H), 7.65 - 7.70 (m, 1H), 9.99 (s, 1H). HRMS (ESI): calculated for [C₁₄H₉F₃O₂ + H]⁺, 267.0627; found 267.0632.

3-(3-(Trifluoromethoxy)phenoxy)benzaldehyde (88): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.27 g, 1.5 mmol), 1-iodo-3-(trifluoromethoxy)benzene (1.3 g, 4.5 mmol), Cs₂CO₃ (1.5 g, 4.5 mmol), *N,N*-dimethylglycine hydrochloride (63 mg, 0.45 mmol) and CuI (79 mg, 0.15 mmol) in dry 1,4-dioxane (8 mL) under air with a drying tube or under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer **88** as a colorless gel (25 mg, 6%). ¹H NMR (300 MHz, CDCl₃) δ: 6.90 (dt, *J* = 2.20, 0.95 Hz, 1H), 6.92 - 6.97 (m, 1H), 6.99 - 7.04 (m, 1H), 7.31 (ddd, *J* = 8.13, 2.56, 1.03 Hz, 1H), 7.37 (t, *J* = 8.20 Hz, 1H), 7.50 - 7.58 (m, 2H), 7.64 - 7.69 (m, 1H), 9.98 (s, 1H). HRMS (ESI): calculated for [C₁₄H₉F₃O₃ + H]⁺, 283.0577; found, 283.0585.

3-(3,5-Dichlorophenoxy)benzaldehyde (89): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.27 g, 1.5 mmol), 1,3-dichloro-5-iodobenzene (1.2 g, 4.5 mmol), Cs₂CO₃ (1.5 g, 4.5 mmol), *N,N*-dimethylglycine hydrochloride (63 mg, 0.45 mmol) and CuI (29 mg, 0.15 mmol) in dry 1,4-dioxane (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer compound **89** as a white solid (160 mg, 67%). ¹H NMR (300 MHz, CDCl₃) δ: 6.90 (d, *J* = 1.76 Hz, 2H), 7.15 (t, *J* = 1.76 Hz, 1H), 7.31 (ddd, *J* = 7.98, 2.56, 1.17 Hz, 1H), 7.51 (dd, *J* = 2.05, 1.46 Hz, 1H), 7.57 (t, *J* = 7.76 Hz, 1H), 7.68 - 7.73 (m, 1H), 10.00 (s, 1H). HRMS (ESI): calculated for [C₁₃H₈Cl₂O₂ + H]⁺, 266.9974; found, 266.9982.

3-(3,5-Difluorophenoxy)benzaldehyde (90): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.27 g, 1.5 mmol), 1,3-difluoro-5-iodobenzene (1.1 g, 4.5 mmol), Cs₂CO₃ (1.5 g, 4.5 mmol), *N,N*-dimethylglycine hydrochloride (63 mg, 0.45 mmol) and CuI (29 mg, 0.15 mmol) in dry 1,4-dioxane (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (10 mL/10 mL) to offer compound **90** as a light yellow oil (133 mg, 38%). ¹H NMR (300 MHz, CDCl₃) δ: 6.47 - 6.63 (m, 3H), 7.31 - 7.36 (m, 1H), 7.53 - 7.61 (m, 2H), 7.71 (dt, *J* = 7.54, 1.21 Hz, 1H), 10.00 (s, 1H). HRMS (ESI): calculated for [C₁₃H₈F₂O₂ + H]⁺, 235.0565; found 235.0573.

3-(3,5-Bis(trifluoromethyl)phenoxy)benzaldehyde (91): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 3-(1,3-dioxan-2-yl)phenol **61** (0.27 g, 1.5 mmol), 1-iodo-3,5-bis(trifluoromethyl)benzene (1.5 g, 4.5 mmol), Cs₂CO₃ (1.5 g, 4.5 mmol), *N,N*-dimethylglycine hydrochloride (63 mg, 0.45 mmol) and CuI (29 mg, 0.15 mmol) in dry 1,4-dioxane (8 mL) under air with a drying tube yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (15 mL/15 mL) to offer **91** as a colorless oil (167 mg, 33%). ¹H NMR (300 MHz, CDCl₃) δ: 7.32 - 7.37 (m, 1H), 7.42 (d, *J* = 0.59 Hz, 2H), 7.55 (dd, *J* = 2.64, 1.46 Hz, 1H), 7.59 - 7.66 (m, 2H), 7.74 - 7.78 (m, 1H), 10.02 (s, 1H). HRMS (ESI): calculated for [C₁₅H₈F₆O₂ + H]⁺, 335.0501; found, 335.0511.

4-((*tert*-Butyldimethylsilyl)oxy)phenol (93): According to a literature procedure,⁴⁵ to the solution of hydroquinone **92** (2.2 g, 20 mmol) in dry DMF (15 mL) was added the mixture of imidazole (2.0 g, 30 mmol), *t*-butyldimethylsilyl chloride (3.0 g, 20 mmol). The desired product was offered as a colorless gel (2.0 g, 45%). ¹H NMR (300 MHz, CDCl₃) δ: 0.16 (s, 6H), 0.97 (s, 9H), 4.50 (br. s, 1H), 6.70 (d, *J* = 1.17 Hz, 4H). HRMS (ESI): calculated for [C₁₂H₂₀O₂Si + H]⁺, 225.1305; found, 225.1316.

6-(4-Hydroxyphenoxy)picolinaldehyde (94): Following the general procedure of Ullmann coupling (work-up method 2) and the acetal hydrolysis (method 1), the suspension of 2-bromo-6-(1,3-dioxan-2-yl)pyridine **38** (0.49 g, 2.0 mmol), 4-((*tert*-butyldimethylsilyl)oxy)phenol **93** (1.4 g, 6.0 mmol), Cs₂CO₃

(2.0 g, 6.0 mmol), *N,N*-dimethylglycine hydrochloride (84 mg, 0.60 mmol) and CuI (38 mg, 0.20 mmol) in dry 1,4-dioxane (10 mL) under air with a drying tube was heated at 90 °C for 6 h to yield the intermediate (370 mg, 16%). following a modified literature procedure,⁴⁶ 1.0 M TBAF-THF solution (0.52 mL, 0.52 mmol) was added slowly dropwise to a stirred solution of the obtained intermediate (182 mg, 0.469 mmol) in dry THF (10 mL). The solution was stirred for 3 h at room temperature followed by dilution with ethyl acetate (50 mL) and washed with sat. aq. NH₄Cl solution (50 mL) and brine (50 mL) sequentially. The organic layer was dried over Na₂SO₄ and evaporated to obtain the crude intermediate. Following the general procedure of acetal hydrolysis (method 2). The crude intermediate was dissolved with THF (6 mL) and 2 M aq. HCl (8 mL) at room temperature. The reaction mixture was heated at 65 °C for 2.5 h to offer compound **94** as a yellow gel (85 mg, 85%). ¹H NMR (300 MHz, CDCl₃) δ: 6.85 - 6.91 (m, 2H), 7.03 - 7.11 (m, 3H), 7.67 (dd, *J* = 7.32, 0.88 Hz, 1H), 7.80 - 7.87 (m, 1H), 9.85 (d, *J* = 0.88 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 115.94, 116.35 (3C), 122.49 (2C), 140.27, 146.89, 150.83, 152.97, 164.37, 192.95. HRMS (ESI): calculated for [C₁₂H₉NO₃ + H]⁺, 216.0655; found, 216.0658.

Methyl 2-((6-formylpyridin-2-yl)oxy)benzoate (96): According to a literature procedure,¹⁸ the suspension of 2-bromo-4-(1,3-dioxan-2-yl)pyridine **38** (0.49 g, 2.0 mmol), methyl 2-hydroxybenzoate (0.46 g, 3.0 mmol), K₃PO₄ (0.85 g, 4.0 mmol), picolinic acid (49 mg, 0.40 mmol), and CuI (38 mg, 0.20 mmol) in dry DMSO (4 mL) under argon yielded the intermediate, which was dissolved with 2 M aq. HCl/THF (8 mL/6 mL) at room temperature. The reaction mixture was heated at 50 °C to offer compound **96** as a light yellow gel (125 mg, 24%). ¹H NMR (300 MHz, CDCl₃) δ: 3.69 (s, 3H), 7.19 (dd, *J* = 8.20, 0.88 Hz, 1H), 7.23 - 7.27 (m, 1H), 7.35 (td, *J* = 7.62, 1.17 Hz, 1H), 7.58 - 7.67, (m, 2H), 7.87 (ddd, *J* = 8.20, 7.32, 0.88 Hz, 1H), 8.03 (dd, *J* = 7.62, 1.76 Hz, 1H), 9.71 (d, *J* = 0.59 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 52.02, 116.04, 124.09, 124.23, 125.46, 131.78, 133.81, 140.16, 150.48, 152.57, 164.02, 165.43, 192.86. HRMS (ESI): calculated for [C₁₄H₁₁NO₄ + H]⁺, 258.0761; found, 258.0765.

4.2. BIOLOGY

4.2.1. Expression and Purification of *M. tuberculosis* Thymidylate Kinase (*Mt*TMPK)

Recombinant *Mt*TMPK was produced in *E. coli* and purified to homogeneity as previously described including slight modifications.⁴⁷ *E. coli* BLi5 competent cells were transformed with the bacterial expression vector pHL50 containing the cDNA sequence encoding full length wild-type *Mt*TMPK (uniprot: P9WKE1). Transformed cells were selected on LB agar plates containing 100 µg/ml carbenicillin and 34 µg/ml chloramphenicol and directly used to inoculate 1 L of 2xYT medium supplemented with the same antibiotics. The cells were grown at 37°C and allowed to reach the late exponential phase of growth (absorbance of 1.5 at 600 nm) at which point 1 mM isopropyl-1-thio-β-d-thiogalactoside (IPTG) was added to the culture medium. After an additional 3-hour incubation period at 37°C, cells were harvested by centrifugation at 8000 x g at 4°C and stored at -80°C until purification. For purification, cells from 1 L culture were resuspended in 50 ml cold lysis buffer containing 50 mM Tris HCl pH 8.0 supplemented with anti-protease cocktail (Roche) and lysed by sonication. After centrifugation at 20000 x g for 30 minutes at 4°C, the filtered bacterial lysate was injected on a 5 ml pre-equilibrated Blue-Sepharose column. The column was washed with lysis buffer and the protein eluted with a 0-2M NaCl gradient (50 mM Tris HCl pH 8.0, 0-2 M NaCl). Fractions containing *Mt*TMPK were pooled and injected on a HiLoad Superdex 75 16/600 column equilibrated with 20 mM Tris HCl pH 7.4, 1 mM EDTA as polishing and desalting steps. *Mt*TMPK fractions were combined and Tris-(2-carboxyethyl)-phosphine (TCEP) was added to 1 mM final concentration before flash-freezing of the protein samples in liquid nitrogen.

4.2.2. *Mt*TMPK enzyme inhibitory assay

The compounds were dissolved in DMSO. The assays were performed at fixed concentrations of ATP (0.5 mM) and dTMP (0.05 mM), and at varying concentrations of tested compound (between 0.0008 and 0.6 mM) using the spectrophotometric assay described by Blondin *et al.*⁴⁸ The reaction medium contains 50 mM Tris-HCl, pH 7.4, 50 mM KCl, 2 mM MgCl₂, 0.2 mM NADH, 1 mM phosphoenol pyruvate, and 2

units each of coupling enzymes (lactate dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase). IC₅₀ values were calculated using KaleidaGraph.

4.2.3. Protein crystallization

Cocrystallization conditions of *Mt*TMPK-inhibitor complexes were screened at 20 °C by the sitting-drop vapor-diffusion method using a 1:1 protein: solution volume ratio and available sparse-matrix crystallization screens. First, thawed *Mt*TMPK samples were concentrated to 6-8 mg/ml and the compound of interest added to the concentrated protein stock. The protein/inhibitor sample was incubated on ice for 1 hour before setting up crystallization trials. Specific crystallization conditions for each cocystal are described below.

For the *Mt*TMPK/**3** complex, the ligand stock solution at 50 mM in 50/50 (v/v) pure DMSO/ pure isopropanol solution was added to the concentrated protein solution stock to reach a final inhibitor concentration of 1 mM. To further increase the solubility of analogue **3**, a 50/50 (v/v) *Mt*TMPK buffer/pure isopropanol solution was added to the protein/inhibitor sample to increase final isopropanol concentration from 1% (v/v) to 1.5% (v/v). An initial hit was obtained in condition 36 from crystal screen II (0.1 M HEPES pH 7.5, 4.3 M NaCl). The crystallization condition was further optimized and the best diffracting crystal obtained after a few weeks at room temperature using the crystallization condition 0.1 M HEPES pH 6.8, 4.45 M NaCl. The crystal was exposed to a cryoprotection buffer obtained by the combination of mother liquor supplemented with 1 mM compound **3** and 10% (v/v) ethylene glycol before being mounted and flash frozen in liquid nitrogen.

Initial efforts to obtain *Mt*TMPK/**33** cocystals led to the obtention of crystals with very limited diffraction power. Better crystals were obtained using the cross-seeding approach starting from in-house grown *Mt*TMPK crystals obtained with compound **33** related inhibitors. In short, *Mt*TMPK cocystals diffracting to limited resolution (3-4 angström) and initially grown in 0.1 M HEPES pH 6.8, 4.40 M NaCl were crushed in 50 µl of stabilizing solution (0.1 M HEPES pH 6.8, 4.50 M NaCl, 1% (v/v) DMSO, 1%

(v/v) isopropanol, 0.5 mM compound **33**) using the seed bead kit (Hampton Research) and serial dilution of seeds with stabilizing solution were performed. The *Mt*TMPK/**33** sample was prepared as previously described for compound **3** complex but using a lower protein concentration (6.0 mg/ml). Crystallization trials were set-up at room temperature using the contemporary seeding approach by mixing 0.3 μ l of *Mt*TMPK/compound **33** sample with 0.2 μ l of crystallization solution and 0.1 μ l of undiluted or diluted seed stock. The best diffracting crystal was obtained after a few weeks at room temperature using the undiluted seed stock and crystallization solution consisting of 0.1 M HEPES pH 6.8, 4.45 M NaCl. This crystal was exposed to a cryoprotection buffer (mother liquor supplemented with 1 mM compound **33** and 25% (w/v) d-glucose) before being mounted and flash frozen in liquid nitrogen.

4.2.3.1. Data collection, structure determination and refinement

X-ray diffraction data for *Mt*TMPK/**3** cocrystal were collected on Proximal beamline at Soleil synchrotron (Paris, France) at a wavelength of 0.9184 Å and a temperature of 100 K on a Dectris Pilatus 6M pixel detector. X-ray measurement for *Mt*TMPK/**33** cocrystal were recorded on ID23-2 beamline at ESRF (Grenoble, France) at a wavelength of 0.87290 Å and a temperature of 100 K on a Dectris Pilatus 6M pixel detector.

All datasets were indexed, processed and scaled using XDS/XSCALE and mtz conversion was performed with XDSCONV keeping five percent of randomly selected reflections for the R_{free} set.⁴⁹ All structures were solved by molecular replacement with PDB input file 4UNR using MOLREP program from the CCP4 suite (Supporting Information, Table S1).⁵⁰ Structures were further refined by one cycle of rigid-body refinement in BUSTER⁵¹ followed by positional and individual isotropic B-factor refinement in BUSTER and PHENIX.⁵² Models were manually improved during the course of the crystallographic refinement using the graphic program COOT.⁵³ For both structures, torsion NCS restraints were used throughout the refinement. Ligand coordinates were generated with the Grade Web Server (<http://grade.globalphasing.org>), which was also used for restraint generation. Ligand molecules were

modeled in sigma-weighted Fo-Fc difference electron density maps in the course of the refinement. TLS refinement with one TLS group definition per chain was applied in the latest stage of the refinement procedure after having all atoms B-factor reset to the Wilson B-factor value. The real-space correlation coefficient (RSCC) is reported as an objective measure of the fit of inhibitor coordinates to electron density and was calculated using Twilight program.⁵⁴ Discovery studio visualizer version 16.1.0 (Dassault Systèmes BIOVIA, San Diego: Dassault Systèmes) was used to analyze and describe the binding mode of inhibitors within the protein. The quality of the final crystal structures was assessed with MOLPROBITY⁵⁵ prior to deposition at the PDB database under the codes 5NRN (*Mt*TMPK/**3**), and 5NRQ (*Mt*TMPK/**33**). Molecular images were generated with PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC). Data collection and refinement statistics are presented in Table S1.

4.2.4. Molecular docking

The molecular modeling calculation was performed using the software packages AutoDock 4.2 on Windows Cygwin and AutodockTools-1.5.6.⁵⁶ The solved X-ray structure of ligand **3** in complex with *Mt*TMPK (PDB entry 5NRN) was used in all docking experiments. The 2D chemical structures and PDB files of compound **3** were drawn and created using ChemDraw 15 and ChemBioDraw 15 separately. The PDBQT file of ligand **3** and *Mt*TMPK were prepared by AutodockTools-1.5.6, which includes atomic partial charges, atom types and the information of the ligand torsional degrees. For the docking, a default grid spacing of 0.375 Å and 60 × 60 × 60 number of grid points were used, which centered the box on the active site of *Mt*TMPK (e.g. the typical π - π stacking between Phe-70 and thymine ring of the ligand).⁵⁷ The Genetic Algorithm-Local Search (GA-LS) method was adopted using default settings. 50 possible conformations were generated by Autodock 4.2 for each docking. A manual selection procedure combining visual inspection in Chimera guided by the Ligplot analysis together with the predicted free energy found for each conformation was used to validate the docked conformations.

4.2.5. In Vitro Cytotoxicity Assay

In vitro cytotoxicity on the MRC-5 *Homo sapiens* long fibroblast cell line (ATCC® CCL-171™) was performed as previously described.⁵⁸ Briefly, the MRC-5 cells were cultured in 75 cm² sterile Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum in a 5% CO₂ atmosphere at 37°C. When a semi-confluent layer of cells was formed, the cells were trypsinized, washed with sterile PBS, seeded into a transparent, flat-bottomed 96-well plate at a density of 4 x 10⁴ cells per well and left for recovery at 37 °C, 5% CO₂ for at least 24 hours. For each compound, a two-fold serial dilution was made in complete DMEM with final concentrations ranging from 128 μM to 0.5 μM. Subsequently, the MRC-5 cells were exposed to the compounds (in triplicate) by adding 100 μL of the serial dilutions to the wells. Test plates were incubated for 3 days in an atmosphere of 5% CO₂ at 37 °C. For the resazurin assay, the cells were washed 2 times with 200 μL PBS and 100 μL resazurin working solution was added per well. Subsequently, the plates were left for incubation at 37°C, 5% CO₂ for 3 hours. To monitor the viable cell number after compound exposure, each well was analyzed using a microplate fluorometer equipped with a 560 nm excitation / 590 nm emission filter set. Tamoxifen was included as positive control (IC₅₀ = 11.1 μM).

4.2.6. Whole-cell activity against *M. tuberculosis* (H37Rv)

MIC determination was performed as previously described.⁵⁹ In brief, test compounds were dissolved in DMSO at a 10 mM stock concentration. *M. tuberculosis* H37Rv cells (ATCC 27294) were cultured until they reached OD_{650nm} 0.2-0.3, subsequently diluted 1000-fold in medium for the MIC determination. Compounds were 2-fold serially diluted in medium into clear, sterile round-bottom 96-well plates (Nunc) at 50 μL per well in duplicate with a concentration range spanning 100-0.049 μM. An equal volume of the diluted cells equaling to approximately 1 × 10⁴ bacteria per well was then added to each well. Plates were incubated for 1 week at 37 °C after which they were read with an enlarging inverted mirror plate reader. The MIC was taken as the lowest concentration that completely inhibited growth. The growth medium was 7H9/glucose/casitone/Tyloxapol, which consisted of (per liter) 4 g glucose, 4.7 g Middlebrook

7H9 broth base, 0.8 g NaCl, 0.3 g Bacto™ casitone and 0.5 mL Tyloxapol. Isoniazid was included as a positive control, and DMSO as negative control.

4.2.7. Efflux-pump studies with *M. tuberculosis* (H37Rv)

Experiments to study efflux were conducted as previously described.¹¹ Briefly, they employed *M. tuberculosis* strains H37Rv (reference), and KO-mutants KO-Tap²⁶, KO-Mmr²⁷, which lack the genes encoding for efflux pumps Tap and Mmr, respectively. Mycobacteria were cultured in Middlebrook 7H9 medium, supplemented with 10% ADC (albumin, dextrose, catalase supplement, BD) and 0.05 % Tween80, at 37 °C. KO-strains were cultured in the same medium as mentioned, with additional supplementation of hygromycin (50 µg/mL). MIC values were determined using resazurin.⁶⁰ Assays were performed in 96-well plates, employing a doubling dilution series starting at 500 µg/mL. Compounds were added in 100 µL at the desired concentration (medium: Middlebrook 7H9 with 10% ADC and 0.5% glycerol supplementation). Then, bacteria were added (100 µL of a suspension containing 10⁵ CFU/mL (determined by optical density, culture in exponential growth phase). After incubation for 6 days at 37 °C, 30 µL resazurin solution (0.01 % W/V) was added to each well, and plates incubated for another 48 h at 37 °C. Assessment of colour change (blue to pink) is indicative for bacterial growth. MIC is defined as the lowest drug concentration that prevents colour change.

For assays with efflux pump inhibitors, verapamil was added at a final concentration of 40 µg/mL and PAβN at 15 µg/mL.

Changes in MIC between strains/experimental conditions were considered significant when the change was at least a 4-fold with respect to the reference strains or reference condition.

Ancillary information

Supporting Information

Details on the data collection and refinement statistics for the cocrystal structures can be found in the Supporting Information.

NMR spectra of prepared final compounds can be found in the Supporting Information.

PDB Codes

Authors will release the atomic coordinates and experimental data upon publication of the manuscript for publication: *Mt*TMPK-3 (PDB code: 5NR5); *Mt*TMPK-33 (PDB code: 5NRQ).

Author information

Corresponding Author

* Serge Van Calenbergh: Tel: +32 (0)9 264 81 24. Fax: +32 (0)9 264 81 46. email: serge.vancalenbergh@ugent.be

Acknowledgements

L.S. thanks the financial support of the Chinese scholarship council (CSC) for a PhD scholarship. F.H. thanks the FWO Flanders for a PhD scholarship. Y.J. tanks CSC (201607060021) for a PhD scholarship. R.M. and S.N.S. gratefully acknowledge infrastructural access and support at crystallographic beamlines PX1 at SOLEIL synchrotron (Gif-sur-Yvette, France) and P14 at PETRA3 synchrotron (Hamburg, Germany), as well as grant support from the Hercules Foundation (AUGE-11-029) and the Flanders Institute for Biotechnology (VIB).

Abbreviations

ADC, albumin, dextrose and catalase supplement; ATCC, American type culture collection; BOM, benzyloxymethyl; cfu/mL, colony forming units per milliliters; DMEM, Dulbecco's modified Eagle's medium; dTMP, thymidine monophosphate; EMB, ethambutol; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IPTG, isopropyl-1-thio- β -D-thiogalactoside; LB, lysogeny broth; KO-Mmr, H37Rv knock out for Mmr efflux pump; KO-Tap, H37Rv knock out for Tap efflux pump; Mtb, *Mycobacterium tuberculosis*; MtTMPK, *Mycobacterium tuberculosis* thymidylate kinase; NCS, noncrystallographic symmetry; NRU, neutral red uptake; PA β N, phenylalanine-arginine β -naphthylamide; RSCC, real-space correlation coefficient; RLU, relative light units; TBDMSCl, *tert*-butyldimethylsilyl chloride; TCEP, tris(2-carboxyethyl)-phosphine; TLS, translation-libration-screw; TMP, deoxythymidine monophosphate; TDP, deoxythymidine diphosphate; dTTP, deoxythymidine triphosphate; TZ, thioridazine.

References

1. WHO, Global tuberculosis report. **2019**.
2. CDC, Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. *MMWR Morb. Mortal. Wkly. Rep.* **1991**, *40* (34), 585-591.
3. Reichard, P., Interactions between deoxyribonucleotide and DNA synthesis. *Annu. Rev. Biochem.* **1988**, *57* (1), 349-374.
4. Huang, S.-H.; Tang, A.; Drisco, B.; Zhang, S.-Q.; Seeger, R.; Li, C.; Jong, A., Human dTMP Kinase: Gene Expression and Enzymatic Activity Coinciding with Cell Cycle Progression and Cell Growth. *DNA and Cell Biology* **1994**, *13* (5), 461-471.
5. Lavie, A.; Vetter, I. R.; Konrad, M.; Goody, R. S.; Reinstein, J.; Schlichting, I., Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. *Nat. Struct. Biol.* **1997**, *4* (8), 601-604.
6. Griffin, J. E.; Gawronski, J. D.; Dejesus, M. A.; Ioerger, T. R.; Akerley, B. J.; Sasseti, C. M., High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. *PLoS Pathog.* **2011**, *7* (9), e1002251.
7. Halgren, T. A., Identifying and Characterizing Binding Sites and Assessing Druggability. *J. Chem. Inf. Model.* **2009**, *49* (2), 377-389.
8. Naik, M.; Raichurkar, A.; Bandodkar, B. S.; Varun, B. V.; Bhat, S.; Kalkhambkar, R.; Murugan, K.; Menon, R.; Bhat, J.; Paul, B.; Iyer, H.; Hussein, S.; Tucker, J. A.; Vogtherr, M.; Embrey, K. J.; McMiken, H.; Prasad, S.; Gill, A.; Ugarkar, B. G.; Venkatraman, J.; Read, J.; Panda, M., Structure guided lead generation for M. tuberculosis thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1,6-naphthyridin-2-one as potent inhibitors. *J. Med. Chem* **2015**, *58* (2), 753-766.
9. Li de la Sierra, I.; Munier-Lehmann, H.; Gilles, A. M.; Bârzu, O.; Delarue, M., X-ray structure of TMP kinase from Mycobacterium tuberculosis complexed with TMP at 1.95 Å resolution. *J. Mol. Biol.* **2001**, *311* (1), 87-100.
10. Fioravanti, E.; Adam, V.; Munier-Lehmann, H.; Bourgeois, D., The Crystal Structure of Mycobacterium tuberculosis Thymidylate Kinase in Complex with 3'-Azidodeoxythymidine Monophosphate Suggests a Mechanism for Competitive Inhibition. *Biochemistry* **2005**, *44* (1), 130-137.
11. Song, L.; Merceron, R.; Gracia, B.; Quintana, A. L.; Risseuw, M. D. P.; Hulpia, F.; Cos, P.; Ainsa, J. A.; Munier-Lehmann, H.; Savvides, S. N.; Van Calenbergh, S., Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors. *J. Med. Chem.* **2018**, *61* (7), 2753-2775.
12. Hopkins, A. L.; Groom, C. R.; Alex, A., Ligand efficiency: a useful metric for lead selection. *Drug Discovery Today* **2004**, *9* (10), 430-431.
13. Piccaro, G.; Poce, G.; Biava, M.; Giannoni, F.; Fattorini, L., Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. *J. Antibiot.* **2015**, *68* (11), 711-714.
14. Lakshminarayana, S. B.; Huat, T. B.; Ho, P. C.; Manjunatha, U. H.; Dartois, V.; Dick, T.; Rao, S. P. S., Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. *J. Antimicrob. Chemother.* **2014**, *70* (3), 857-867.
15. Song, L.; Risseuw, M. D. P.; Froeyen, M.; Karalic, I.; Goeman, J.; Cappoen, D.; Van der Eycken, J.; Cos, P.; Munier-Lehmann, H.; Van Calenbergh, S., Elaboration of a proprietary

- thymidylate kinase inhibitor motif towards anti-tuberculosis agents. *Bioorg. Med. Chem.* **2016**, *24* (21), 5172-5182.
16. Ma, D.; Cai, Q., N,N-Dimethyl glycine-promoted Ullmann coupling reaction of phenols and aryl halides. *Org. Lett.* **2003**, *5* (21), 3799-3802.
 17. Kori, M.; Imaeda, T.; Nakamura, S.; Toyofuku, M.; Honda, E.; Asano, Y.; Ujikawa, O.; Mochizuki, M. Heterocyclic compound and use thereof. 2012.
 18. Maiti, D.; Buchwald, S. L., Cu-Catalyzed arylation of phenols: synthesis of sterically hindered and heteroaryl diaryl ethers. *J. Org. Chem.* **2010**, *75* (5), 1791-1794.
 19. Plobeck, N.; Delorme, D.; Wei, Z.-Y.; Yang, H.; Zhou, F.; Schwarz, P.; Gawell, L.; Gagnon, H.; Pelcman, B.; Schmidt, R.; Yue, S. Y.; Walpole, C.; Brown, W.; Zhou, E.; Labarre, M.; Payza, K.; St-Onge, S.; Kamassah, A.; Morin, P.-E.; Projean, D.; Ducharme, J.; Roberts, E., New diarylmethylpiperazines as potent and selective nonpeptidic δ opioid receptor agonists with increased in vitro metabolic stability. *J. Med. Chem* **2000**, *43* (21), 3878-3894.
 20. Saccomano, N. A.; Vinick, F. J.; Koe, B. K.; Nielsen, J. A.; Whalen, W. M.; Meltz, M.; Phillips, D.; Thaddeo, P. F.; Jung, S.; Chapin, D. C.; Lebel, L. A.; Russo, L. L.; Helweg, D. L.; Johnson Jr, J. L.; Ives, J. L.; Williams, I. H., Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkoxy)-4-methoxyphenyl-2-imidazolidinones. *J. Med. Chem* **1991**, *34* (1), 291-298.
 21. Liu, J.; Barry, C. E.; Besra, G. S.; Nikaido, H., Mycolic acid structure determines the fluidity of the Mycobacterial cell wall. *J. Biol. Chem.* **1996**, *271* (47), 29545-29551.
 22. Nikaido, H., Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. *Semin. Cell Dev. Biol.* **2001**, *12* (3), 215-223.
 23. Topliss, J. G., Utilization of operational schemes for analog synthesis in drug design. *J. Med. Chem* **1972**, *15* (10), 1006-1011.
 24. Chein, R.-J.; Corey, E. J., Strong conformational preferences of heteroaromatic ethers and electron pair repulsion. *Org. Lett.* **2010**, *12* (1), 132-135.
 25. Viveiros, M.; Martins, M.; Rodrigues, L.; Machado, D.; Couto, I.; Ainsa, J.; Amaral, L., Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. *Expert Rev. Anti-Infect. Ther.* **2012**, *10* (9), 983-998.
 26. Ainsa, J. A.; Blokpoel, M. C. J.; Ota, I.; Young, D. B.; De Smet, K. A. L.; Martín, C., Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in *Mycobacterium fortuitum* and *Mycobacterium tuberculosis*. *J. Bacteriol.* **1998**, *180* (22), 5836-5843.
 27. Rodrigues, L.; Villellas, C.; Bailo, R.; Viveiros, M.; Ainsa, J. A., Role of the Mmr efflux pump in drug resistance in *Mycobacterium tuberculosis*. *Antimicrobial agents and chemotherapy* **2013**, *57* (2), 751-757.
 28. Dashti, Y.; Grkovic, T.; Quinn, R. J., Predicting natural product value, an exploration of anti-TB drug space. *Nat. Prod. Rep.* **2014**, *31* (8), 990-998.
 29. Ekins, S.; Freundlich, J. S.; Choi, I.; Sarker, M.; Talcott, C., Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. *Trends Microbiol.* **2011**, *19* (2), 65-74.
 30. Makarov, V.; Lechartier, B.; Zhang, M.; Neres, J.; van der Sar, A. M.; Raadsen, S. A.; Hartkoorn, R. C.; Ryabova, O. B.; Vocat, A.; Decosterd, L. A.; Widmer, N.; Buclin, T.; Bitter, W.; Andries, K.; Pojer, F.; Dyson, P. J.; Cole, S. T., Towards a new combination therapy for tuberculosis with next generation benzothiazinones. *EMBO Mol. Med.* **2014**, *6* (3), 372-383.

31. Guardia, A.; Baiget, J.; Cacho, M.; Perez, A.; Ortega-Guerra, M.; Nxumalo, W.; Khanye, S. D.; Rullas, J.; Ortega, F.; Jimenez, E.; Perez-Herran, E.; Fraile-Gabaldon, M. T.; Esquivias, J.; Fernandez, R.; Porras-De Francisco, E.; Encinas, L.; Alonso, M.; Giordano, I.; Rivero, C.; Miguel-Siles, J.; Osende, J. G.; Badiola, K. A.; Rutledge, P. J.; Todd, M. H.; Remuinan, M.; Alemparte, C., Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis. *J. Med. Chem.* **2018**, *61* (24), 11327-11340.
32. Rodriguez-Rivera, F. P.; Zhou, X.; Theriot, J. A.; Bertozzi, C. R., Visualization of mycobacterial membrane dynamics in live cells. *J. Am. Chem. Soc.* **2017**, *139* (9), 3488-3495.
33. Piddock, L. J. V.; Williams, K. J.; Ricci, V., Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. *Journal of Antimicrobial Chemotherapy* **2000**, *45* (2), 159-165.
34. de Keijzer, J.; Mulder, A.; de Haas, P. E. W.; de Ru, A. H.; Heerkens, E. M.; Amaral, L.; van Soolingen, D.; van Veelen, P. A., Thioridazine alters the cell-envelope permeability of Mycobacterium tuberculosis. *J. Proteome Res.* **2016**, *15* (6), 1776-1786.
35. Greenwood, D. J.; Dos Santos, M. S.; Huang, S.; Russell, M. R. G.; Collinson, L. M.; MacRae, J. I.; West, A.; Jiang, H.; Gutierrez, M. G., Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages. *Science* **2019**, *364* (6447), 1279-1282.
36. Richter, M. F.; Drown, B. S.; Riley, A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J., Predictive compound accumulation rules yield a broad-spectrum antibiotic. *Nature* **2017**, *545* (7654), 299-304.
37. Yuan, T.; Sampson, N. S., Hit Generation in TB Drug Discovery: From Genome to Granuloma. *Chem. Rev.* **2018**, *118* (4), 1887-1916.
38. Tanaka, K.; Yamamoto, E.; Watanabe, N. Preparation of pyridine derivatives substituted with heterocycle and phosphonoamino and antifungal agents containing the same. WO2008136324A1, 2008.
39. Agarwal, R.; Bhirud, S. B.; Bijukumar, G.; Khude, G. D., Expedient Synthesis of Rupatadine. *Synth. Commun.* **2007**, *38* (1), 122-127.
40. Arikan, F.; Li, J.; Menche, D., Diastereodivergent aldol reactions of β -alkoxy ethyl ketones: modular access to (1,4)-syn and -anti polypropionates. *Org. Lett.* **2008**, *10* (16), 3521-3524.
41. Gopinath, V. S.; Pinjari, J.; Dere, R. T.; Verma, A.; Vishwakarma, P.; Shivahare, R.; Moger, M.; Kumar Goud, P. S.; Ramanathan, V.; Bose, P.; Rao, M. V. S.; Gupta, S.; Puri, S. K.; Launay, D.; Martin, D., Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. *Eur. J. Med. Chem.* **2013**, *69*, 527-536.
42. Mjalli, A. M.; Jones, D.; Gohimmukkula, D. R.; Huang, G.; Zhu, J.; Rao, M.; Andrews, R. C.; Ren, T. Benzazole derivatives and their preparation, compositions, and methods of use as β -secretase inhibitors. WO2006099379A2, 2006.
43. Ghosh, A. K.; Liu, C.; Devasamudram, T.; Lei, H.; Swanson, L. M.; Ankala, S. M.; Lilly, J. C.; Bilcer, G. M. Isophthalamide derivatives inhibiting beta-secretase activity. 2009.
44. Apodaca, R.; Breitenbucher, J. G.; Chambers, A. L.; Seierstad, M.; Xiao, W. Oxazolyl piperidine modulators of fatty acid amide hydrolase. 2007.
45. Shiyama, T.; Furuya, M.; Yamazaki, A.; Terada, T.; Tanaka, A., Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. *Bioorg. Med. Chem.* **2004**, *12* (11), 2831-2841.
46. Kishore Kumar, G. D.; Natarajan, A., Total synthesis of ovalifoliolatin B, acerogenins A and C. *Tetrahedron Lett.* **2008**, *49* (13), 2103-2105.

47. Munier-Lehmann, H.; Chaffotte, A.; Pochet, S.; Labesse, G., Thymidylate kinase of *Mycobacterium tuberculosis*: A chimera sharing properties common to eukaryotic and bacterial enzymes. *Protein Sci.* **2001**, *10* (6), 1195-1205.
48. Blondin, C.; Serina, L.; Wiesmuller, L.; Gilles, A. M.; Barzu, O., Improved spectrophotometric assay of nucleoside monophosphate kinase activity using the pyruvate kinase/lactate dehydrogenase coupling system. *Anal. Biochem.* **1994**, *220* (1), 219-221.
49. Kabsch, W., Integration, scaling, space-group assignment and post-refinement. *Acta Crystallogr., Sect. D* **2010**, *66* (2), 133-144.
50. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S., Overview of the CCP4 suite and current developments. *Acta Crystallogr., Sect. B: Struct. Sci.* **2011**, *67* (4), 235-242.
51. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O.; Vonrhein, C., BUSTER version 2.11.5 Global phasing Ltd. **2016**.
52. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallographica Section D* **2010**, *66* (2), 213-221.
53. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K., Features and development of Coot. *Acta Crystallogr., Sect. D* **2010**, *66* (4), 486-501.
54. Pozharski, E.; Weichenberger, C. X.; Rupp, B., Techniques, tools and best practices for ligand electron-density analysis and results from their application to deposited crystal structures. *Acta Crystallogr., Sect. D* **2013**, *69* (2), 150-167.
55. Chen, V. B.; Arendall, W. B., III; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C., MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr., Sect. D* **2010**, *66* (1), 12-21.
56. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30* (16), 2785-2791.
57. Calenbergh, S. V.; Pochet, S.; Munier-Lehmann, H., Drug Design and Identification of Potent Leads Against *Mycobacterium tuberculosis* Thymidine Monophosphate Kinase. *Curr. Top. Med. Chem.* **2012**, *12* (7), 694-705.
58. Hulpia, F.; Van Hecke, K.; Franca da Silva, C.; da Gama Jaen Batista, D.; Maes, L.; Caljon, G.; de Nazare, C. S. M.; Van Calenbergh, S., Discovery of novel 7-aryl 7-deazapurine 3'-deoxy-ribofuranosyl nucleosides with potent activity against *Trypanosoma cruzi*. *J. Med. Chem.* **2018**, *61* (20), 9287-9300.
59. Makowska-Grzyska, M.; Kim, Y.; Gorla, S. K.; Wei, Y.; Mandapati, K.; Zhang, M.; Maltseva, N.; Modi, G.; Boshoff, H. I.; Gu, M.; Aldrich, C.; Cuny, G. D.; Hedstrom, L.; Joachimiak, A., *Mycobacterium tuberculosis* IMPDH in complexes with substrates, products and antitubercular compounds. *PLoS One* **2015**, *10* (10), e0138976.
60. Palomino, J.-C.; Martin, A.; Camacho, M.; Guerra, H.; Swings, J.; Portaels, F., Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrobial agents and chemotherapy* **2002**, *46* (8), 2720-2722.

Table of contents graphic

